USO DE UMA COMPOSIÇÃO COMPREENDENDO UMA PARTÍCULA DE VÍRUS ADENO-ASSOCIADO RECOMBINANTE (RAAV)
Patent Information
- Application Number
- BR122026020378
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-09-02
- Filing Date
- 2017-09-01
- Publication Date
- 2026-11-10
AI Technical Summary
Therapeutic proteins administered intravenously or directly to the brain do not cross the blood-brain barrier or are not widely distributed in the brain, posing a challenge in treating central nervous system diseases like Alzheimer's disease.
Delivering recombinant adeno-associated virus (rAAV) particles containing a vector with a nucleic acid encoding a therapeutic protein to non-CNS or non-ocular cells, which express and secrete the protein into the systemic circulation, allowing it to cross the blood-brain or blood-ocular barriers and reach the target tissues.
Effectively delivers therapeutic proteins to the CNS or ocular tissues without direct administration, enhancing treatment efficacy for diseases such as Alzheimer's and lysosomal storage disorders.
Description
1 / 69 USE OF A COMPOSITION COMPRISING A RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLE (RAAV) Split order BR112019004353-5. Related Orders
[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 383,274, filed Friday, September 2, 2016. All content of the prior application is incorporated into this application by reference, including all text, tables, and sequence listing. Introduction
[0002] The treatment of central nervous system (CNS) diseases, for example, genetic brain diseases such as Alzheimer's disease, remains an intractable problem. One of the main problems in treating brain diseases is that therapeutic proteins, when administered intravenously, do not cross the blood-brain barrier, or when administered directly to the brain, are not widely distributed. Thus, therapies for the treatment of Alzheimer's disease need to be developed.
[0003] There are several different isoforms of human apolipoprotein E (ApoE), the presence of some of these isoforms in the brain increases the risk of Alzheimer's disease (AD), while the presence of other isoforms decreases the risk of AD. The presence of the ApoE ε4 isoform is a strong genetic risk factor for late-onset sporadic AD. (Casellano et al., Sci Transl Med, 3 (89): 89ra57 (June 29, 2011)). The ApoE ε4 allele strongly increases the risk of AD and decreases the age of onset. On the other hand, the presence of the ApoE ε2 allele appears to decrease the risk of AD. It is suggested that human ApoE isoforms differentially affect the clearance or synthesis of amyloid-β (Αβ) in vivo. Summary
[0004] In certain embodiments, the invention provides a Petition 870260081961, dated 08 / 13 / 2026, pp. 157 / 305 2 / 69 A method for treating a disease in a mammal comprising delivering to a non-mammalian central nervous system (CNS) cell, organ or tissue, for delivery to the mammalian CNS (e.g., brain). In certain embodiments, the invention provides a method for treating a disease in a mammal comprising delivering to a non-ocular mammalian cell, organ or tissue, for delivery to mammalian ocular cells, organs or tissues.
[0005] The mammal can be administered an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV terminal inverted repeats in a manner effective to infect a non-CNS cell, organ, or tissue. The mammal can be administered an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a therapeutic protein inserted between a pair of AAV terminal inverted repeats in a manner effective to infect a non-ocular cell, organ, or tissue.
[0006] In certain embodiments, a non-CNS cell, organ, or tissue and a non-ocular cell, organ, or tissue includes a mammalian endocrine cell, organ, or tissue. Exemplary endocrine cells, organs, or tissues include liver cells, organs, and tissues, and pancreatic cells, organs, and tissues. In certain embodiments, a liver cell, organ, or tissue is, or comprises, hepatocytes.
[0007] In certain embodiments, the invention provides a method for delivering a protective ApoE isoform to the CNS of a non-rodent mammal by means of delivery or administration to a non-CNS cell, organ or tissue (e.g., other than the cerebrospinal fluid (CSF) or brain) of the non-rodent mammal. In one embodiment, an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding the isoform Petition 870260081961, dated 08 / 13 / 2026, pages 158 / 305 3 / 69 A protective ApoE isoform is inserted between a pair of inverted terminal repeats of AAVs (ITRs) in a manner that effectively infects non-CNS cells in non-rodent mammals, such that the non-CNS cells secrete the protective ApoE isoform into the mammalian systemic circulation (vasculature or blood vessels). The protective ApoE isoform in the circulation crosses the blood-brain barrier and enters the CNS (e.g., cerebrospinal fluid (CSF) or brain, such as the brain parenchyma).
[0008] In certain embodiments, the invention provides a method for delivering TPP1 (tripeptidyl peptidase I), CLN3 (Battenin), PPT1 (protein palmitoyl thioesterase I), CLN6 (neuronal lipofuscinosis ceroidal protein 6) or CLN8 to the CNS of a non-rodent mammal, by means of delivery or administration to a non-CNS cell, organ or tissue (e.g., not to the cerebrospinal fluid (CSF) or brain) of the non-rodent mammal. In one embodiment, an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding TPP1, CLN3, PPT1, CLN6, or CLN8 is inserted between a pair of inverted terminal repeats of AAV in a manner effective to infect non-CNS cells in non-rodent mammals, such that the non-CNS cells secrete TPP1, CLN3, PPT1, CLN6, or CLN8 into the mammalian systemic circulation (vasculature or blood vessels).TPP1, CLN3, PPT1, CLN6, or CLN8 in the circulation cross the blood-brain barrier and enter the CNS (e.g., cerebrospinal fluid (CSF) or brain, such as the brain parenchyma).
[0009] In certain embodiments, the invention provides a method for delivering a therapeutic protein to an ocular cell, tissue, or organ of a non-rodent mammal, by means of delivery or administration to a non-ocular cell, organ, or tissue of the non-rodent mammal. In one embodiment, an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding the therapeutic protein is inserted between a pair of terminal inverted AAV repeats in a manner effective for non-ocular cells, tissue, or organs in the non-rodent mammal. Petition 870260081961, dated 08 / 13 / 2026, page 159 / 305 4 / 69 rodent, so that non-ocular cells, tissue or organ secrete the therapeutic protein into the systemic circulation (vasculature or blood vessels) of the mammal. The therapeutic protein in circulation crosses the blood-brain barrier and enters the ocular cell, tissue or organ.
[0010] In certain embodiments, the invention provides a method for transfecting mammalian non-CNS cells, organs or tissues, to deliver to a mammalian CNS (e.g., cerebrospinal fluid (CSF) or brain, such as brain parenchyma). In one aspect, a method includes delivering or administering to a mammalian endocrine cell, tissue or organ an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a protective ApoE isoform inserted between a pair of inverted terminal repeats of AAV in a manner effective to infect an endocrine cell, tissue or organ (e.g., liver and / or pancreas) for expression and subsequent delivery of a protective ApoE isoform to the mammalian CNS (e.g., cerebrospinal fluid (CSF) or brain, such as brain parenchyma), for example, via systemic circulation (vasculature or blood vessels).In another aspect, a method involves delivering or administering to the mammalian liver and / or pancreas an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a protective ApoE isoform inserted between a pair of inverted terminal repeats of AAV in a manner effective to infect an endocrine cell, tissue, or organ (e.g., liver and / or pancreas) for expression and delivery of a protective ApoE isoform into the mammalian CNS (e.g., cerebrospinal fluid (CSF) or brain, such as brain parenchyma), for example, via systemic circulation (vasculature or blood vessels).
[0011] As used in this application, the term “protective ApoE isoform” refers to ApoE isoforms that attenuate one or more symptoms or indications of Alzheimer’s disease (e.g., physical, physiological, biochemical, histological, behavioral). An isoform Petition 870260081961, dated 08 / 13 / 2026, pp. 160 / 305 5 / 69 protective ApoE also refers to ApoE isoforms that can reduce the risk of Alzheimer's disease by at least 5%, such as 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or more.
[0012] In certain embodiments, the methods of the invention provide treatment for a lysosomal storage disease or disorder. In certain embodiments, the disease or disorder is a deficiency or defect in the expression or activity of TPP1 (tripeptidyl peptidase I), CLN3 (Battenin), PPT1 (palmitoyl thioesterase protein I), CLN6 (neuronal ceroid lipofuscinosis protein 6), or CLN8. In certain embodiments, the disease is a neurodegenerative disease, such as neuronal ceroid lipofuscinosis (NCL), such as infantile NCL, late-onset infantile NCL, juvenile NCL (Batten disease), and adult NCL. Other lysosomal storage diseases treated according to the invention affect other tissues / organs, such as Mucopolysaccharidoses (MPS IV and MPS VII), and can be treated with an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a therapeutic protein according to the methods set forth in this application.
[0013] In certain modalities, the disease or disorder is a neurodegenerative disease such as neuronal ceroid lipofuscinosis (NCL), such as infantile NCL, late infantile NCL, juvenile NCL (Batten disease) and adult NCL inserted between a pair of inverted terminal repeats of AAV in an effective way to infect the liver and / or pancreas for expression and distribution of a therapeutic protein to the mammalian CNS, for example, through the systemic circulation (vasculature or blood vessels). In one aspect, a method involves delivering or administering to the mammalian liver and / or pancreas an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a TPP1, CLN3, PPT1, CLN6, or CLN8 inserted between a pair of AAV terminal inverted repeats in a manner effective for infecting the liver and / or pancreas for expression and delivery of TPP1, CLN3, PPT1, CLN6, or CLN8 to the CNS (e.g., brain). Petition 870260081961, dated 08 / 13 / 2026, page 161 / 305 6 / 69 of mammals, for example, through systemic circulation (vasculature or blood vessels).
[0014] In certain modalities, the mammal is a non-rodent mammal. In certain modalities, the non-rodent mammal is a primate, horse, sheep, goat, pig, or dog. In certain modalities, the mammal is human. In certain modalities, the primate is a human. In certain modalities, the human is a newborn, an infant, a child, an adolescent, or a young adult.
[0015] In certain modalities, the mammal (e.g., human) has a deficiency or disorder of the CNS treatable by gene replacement or suppression therapy.
[0016] In certain embodiments, the encoded ApoE protective isoform has at least about 70% or more identity (e.g., 70-80% or 80-90%) with mammalian ApoE ε2 (e.g., primate, such as a human). In certain embodiments, the encoded ApoE protective isoform has 90-100% identity with mammalian ApoE ε2 (e.g., primate, such as a human).
[0017] In certain embodiments, the encoded TPP1 has at least about 70% or more identity (e.g., 70-80% or 80-90%) with a mammalian TPP1 (e.g., primate, such as a human). In certain embodiments, the encoded TPP1 has 90-100% identity with a mammalian TPP1 (e.g., primate, such as a human).
[0018] In certain embodiments, the encoded CLN3, PPT1, CLN6, or CLN8 has at least about 70% or more identity (e.g., 70-80% or 80-90%) with a mammalian CLN3, PPT1, CLN6, or CLN8 (e.g., primate, such as a human). In certain embodiments, the encoded CLN3, PPT1, CLN6, or CLN8 has 90-100% identity with a mammalian CLN3, PPT1, CLN6, or CLN8 (e.g., primate, such as a human). Petition 870260081961, dated 08 / 13 / 2026, p. 162 / 305 7 / 69
[0019] In certain embodiments, the encoded Galactosamine-6-sulfatase has at least about 70% or more identity (e.g., 70-80% or 80-90%) with a mammalian Galactosamine-6-sulfatase (e.g., primate, such as a human). In certain embodiments, the encoded Galactosamine-6-sulfatase has 90-100% identity with a mammalian Galactosamine-6-sulfatase (e.g., primate, such as a human).
[0020] In certain embodiments, the encoded beta-glucuronidase has at least about 70% or more identity (e.g., 70-80% or 80-90%) to a mammalian beta-glucuronidase (e.g., primate, such as a human). In certain embodiments, the encoded beta-glucuronidase has 90-100% identity to a mammalian beta-glucuronidase (e.g., primate, such as a human).
[0021] In certain embodiments, codon-optimized nucleic acid variants encoding therapeutic proteins are employed in a vector. In certain respects, such codon-optimized nucleic acid variants provide increased transcription and / or translation of the encoded therapeutic protein. Such codon-optimized nucleic acid variants may exhibit increased expression, for example, 0.5-10 times for certain codon-optimized nucleic acid variants when compared with non-optimized codon nucleic acid encoding therapeutic proteins.
[0022] In certain embodiments, reduced cytosine-guanine dinucleotide (CpG) nucleic acid variants encoding therapeutic proteins are employed in a vector. Such reduced cytosine-guanine dinucleotide (CpG) nucleic acid variants include variants that exhibit increased expression, for example, 0.5-10 times for certain reduced CpG nucleic acid variants compared to non-reduced CpG nucleic acid encoding therapeutic proteins.
[0023] In one embodiment, a variant of acid Petition 870260081961, dated 08 / 13 / 2026, p. 163 / 305 8 / 69 nucleic acid encoding a therapeutic protein has reduced cytosine-guanine dinucleotide (CpG) content compared to unreduced CpG nucleic acid encoding the protein. In particular aspects, a nucleic acid variant has at least 10 fewer cytosine-guanine dinucleotides (CpG) than unreduced CpG nucleic acid encoding a therapeutic protein. In further particular aspects, a nucleic acid variant has no more than 20 CpGs; no more than 15 CpGs; no more than 10 CpGs; or no more than 5 CpGs. In more particular aspects, a nucleic acid variant has at most 4 CpGs; 3 CpGs; 2 CpGs; or 1 CpG. In yet another particular aspect, a nucleic acid variant encoding a therapeutic protein has no cytosine-guanine dinucleotides (CpG).
[0024] In certain embodiments, rAAV vectors include ITRs and / or capsids based on, or possessing, sequence identity with ITRs and / or capsids of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV10, AAV10, AAV12, AAV12, LK01, LK02, LK03, AAV4-1 and / or AAV2i8. In certain embodiments, rVAA vectors include variants possessing less than 100% sequence identity with ITRs and / or capsids of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, LK01, LK02, LK03, AAV 4-1 and / or AAV-2i8. The variants include amino acid insertions, additions, substitutions, and deletions. In particular, the variants are presented in WO 2013 / 158879 (International Application PCT / US2013 / 037170), WO 2015 / 013313 (International Application PCT / US2014 / 047670) and US 2013 / 0059732 (US Application No. 13 / 594,773, disclosing LK01, LK02, LK03, etc.).
[0025] In certain embodiments, the rAAV vector comprises one or more ITRs and / or capsids (VP1, VP2 and / or VP3) with at least 70-80%, 80-90% or 90-99% identity with AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, LK01, LK02, LK03, AAV 4-1 and / or AAV-2i8. In certain embodiments, an rAAV vector Petition 870260081961, dated 08 / 13 / 2026, pp. 164 / 305 9 / 69 comprises ITR(s) and / or capsid(s) (VP1, VP2 and / or VP3) with 75% or more sequence identity (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, etc.) for any of the ITRs and / or capsids of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, LK01, LK02, LK03, AAV 4-1 and / or AAV-2i8. In particular aspects,
[0026] In certain embodiments, the rAAV vector comprises one or more ITRs and / or capsids (VP1, VP2 and / or VP3) with 100% identity to the AAV2 capsid VP1, VP2 and / or VP3 AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, LK01, LK02, LK03, AAV 4-1 and / or AAV-2i8.
[0027] In additional particular embodiments, an rAAV vector comprises an AAV serotype or an AAV pseudotype comprising an AAV capsid serotype other than an ITR serotype. The rAAV pseudotype, in which an AAV capsid serotype differs from an ITR serotype, may consist of ITR(s) and / or capsid(s) (VP1, VP2, and / or VP3) with 75% or more sequence identity (e.g., 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, etc.) for any ITRs and / or capsids of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, LK01, LK02, LK03, AAV 4-1 and / or AAV-2i8, provided that the serotypes of ITRs and capsids are different.
[0028] In particular aspects, an AAV vector comprises a VP1, VP2 and / or VP3 capsid sequence having 100% identity with any one of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, LK01, LK02, LK03, AAV 4-1 and / or AAV-2i8 and one or more ITRs of a distinct serotype, for example, an AAV2 ITR with an AAV1 capsid (AAV 2 / 1), an AAV6 ITR with an AAV1 capsid (AAV 6 / 1), an AAV2 ITR with an LK01 capsid (AAV 2 / LK03), an AAV2 ITR with an AAV 4-1 capsid (AAV 2 / 4-1), an AAV6 ITR with one Petition 870260081961, dated 08 / 13 / 2026, pages 165 / 305 10 / 69 capsid LK01 (AAV 6 / LK03), or an ITR AAV6 with an AAV 4-1 capsid (AAV 6 / 4-1).
[0029] rAAV vectors may include additional components or elements that act in cis or trans. In particular embodiments, a vector, such as the rAAV vector, additionally includes an intron, an expression control element, one or more ITRs (e.g., any of: AAV1, AAV2, AAV3, AAV4, AAV10, AAV11, AAV12, LK01, LK02, LK03, AAV 4-1 and / or AAV-2i8, or a combination thereof), a polynucleotide filler sequence and / or a poly A signal. In particular aspects, an intron is within, or flanks, a nucleic acid encoding a therapeutic protein, and / or an expression control element is operatively linked to the nucleic acid encoding a therapeutic protein, and / or an AAV ITR(s) flanks the 5' or 3' terminus of the nucleic acid encoding a therapeutic protein, and / or a polynucleotide filler sequence flanks the 5' or 3' terminus of the nucleic acid that It encodes a therapeutic protein.
[0030] In particular embodiments, an expression control element comprises a constitutive or regulable control element, or a promoter or tissue-specific expression control element. In particular aspects, an expression control element comprises an enhancer. In certain aspects, an expression control element (e.g., promoter or enhancer) confers expression in a liver cell, organ or tissue or pancreatic cell, organ or tissue. In particular aspects, an expression control element (e.g., promoter or enhancer) comprises an element that confers expression in the liver (e.g., a TTR promoter or a mutant TTR promoter).
[0031] In certain embodiments, the invention provides an rAAV particle containing a vector comprising a nucleic acid encoding a protective ApoE isoform inserted between a pair of AAV ITRs. Petition 870260081961, dated 08 / 13 / 2026, page 166 / 305 11 / 69 for use in transfecting a non-CNS cell, organ, or tissue in a mammal to generate a therapeutic result in the CNS. In one aspect, one use is to treat Alzheimer's disease in a mammal.
[0032] In certain embodiments, the invention provides an rAAV particle containing a vector comprising a nucleic acid encoding a TPP1 inserted between a pair of AAV ITRs for use in transfecting a non-CNS cell, organ, or tissue in a mammal to generate a therapeutic outcome in the CNS. In one aspect, a use is for treating neuronal ceroid lipofuscinosis in a mammal.
[0033] In certain embodiments, the invention provides an rAAV particle containing a vector comprising a nucleic acid encoding a CLN3, PPT1, CLN6 or CLN8 inserted between a pair of AAV ITRs for use in transfecting a non-CNS cell, organ or tissue in a mammal to generate a therapeutic outcome in the CNS. In one aspect, a use is to treat Batten disease in a mammal.
[0034] In certain embodiments, the invention provides an rAAV particle containing a vector comprising a nucleic acid encoding a Galactosamine-6-sulfatase inserted between a pair of AAV ITRs for use in transfecting a non-ocular cell, organ, or tissue in a mammal to generate a therapeutic outcome in the ocular cell, tissue, or organ. In one aspect, a use is for the treatment of MPS IV.
[0035] In certain embodiments, the invention provides an rAAV particle containing a vector comprising a nucleic acid encoding a beta-glucuronidase inserted between a pair of AAV ITRs for use in transfecting a non-ocular cell, organ, or tissue in a mammal to generate a therapeutic outcome in the ocular cell, tissue, or organ. In one aspect, a use is for treating MPS VII.
[0036] In certain embodiments, rAAV vectors are supplied, delivered, delivered or used at a dose in a range of approximately 1x10⁸-1x10¹⁰, 1x10⁻¹⁰, 1x10¹¹-1x10¹², 1x10¹²-1x10¹³, or Petition 870260081961, dated 08 / 13 / 2026, p. 167 / 305 12 / 69 1x10¹³–1x10¹⁴ vector genomes per kilogram (vg / kg) of mammal. In certain aspects, rAAV vectors are administered or used at a dose of less than 1x10¹² vector genomes per kilogram (vg / kg). In certain aspects, rAAV vectors are administered or used at a dose of approximately 5x10¹¹ vector genomes per kilogram (vg / kg) of mammal.
[0037] In more particular aspects, the quantities of rAAV vectors supplied, administered, delivered or used are at least 1x1010 genomes (vg) per kilogram (vg / kg) of mammalian weight, or between about 1x1010 to 1x1011vg / kg of mammalian weight, or between about 1x1011 to 1x1012vg / kg (e.g., about 2x1011vg / kg or about 1x1011vg / kg) 2x1o11a 3x1o11vg / kg or about 3x1o11a 4x1o11vg / kg or about 4x1o11a 5x1011vg / kg or about 5x1011a 6x1011vg / kg or about 6x1011a 7x1011vg / kg or about 7x1011a 8x1011vg / kg or about 8x1011a 9x1011vg / kg or about 9x1011a 1x1012vg / kg) of the mammal's weight, or between about 1x1012a and 1x1013vg / kg of the mammal's weight, to achieve a desired therapeutic effect. Additional specific amounts may be in a range of about 5x1010 to 1x1010 vector genomes (vg) per kilogram (vg / kg) of mammalian weight, or in a range of about 1x1010 to 5x1011 vg / kg of mammalian weight, or in a range of about 5x1011 to 1x1012 vg / kg of mammalian weight, or in a range of about 1x1012 to 5x1013 vg / kg of mammalian weight, to achieve a desired therapeutic effect.
[0038] In certain embodiments, the methods and / or uses of the invention, as presented herein, do not induce or produce in the mammal a substantial immune response against the therapeutic protein and / or the rAAV particle. In certain aspects, the mammal does not produce a substantial humoral immune response against the therapeutic protein and / or the rAAV particle. In certain aspects, a substantial immune response (e.g., humoral) against the therapeutic protein and / or the rAAV particle is not produced for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 continuous days, weeks or months. Petition 870260081961, dated 08 / 13 / 2026, pp. 168 / 305 13 / 69
[0039] A substantial immune response in the context of treatment is considered to be one that significantly reduces efficacy. Thus, in the case of a CNS disorder or disease, it would be a substantial immune response if there were no detectable efficacy in the treatment of the CNS disorder or disease. Therefore, a substantial immune response does not mean a minimal immune response or one that does not result in a significant loss or reduction of efficacy in the context of treatment.
[0040] In certain modalities, the mammal does not develop a detectable immune response against the therapeutic protein and / or rAAV particle. In certain modalities, the mammal does not develop a detectable humoral immune response against the therapeutic protein and / or the rAAV particle.
[0041] In certain embodiments, the mammal does not develop an immune response (e.g., humoral) against the therapeutic protein and / or the rAAV particle sufficient to block a therapeutic effect of the therapeutic protein. In certain aspects, the mammal does not produce an immune response (e.g., humoral) against the therapeutic protein and / or the rAAV particle sufficient to block the therapeutic effect for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 continuous days, weeks or months.
[0042] In certain embodiments, empty capsids may be included in rAAV vectors, methods and uses. If desired, empty AAV capsids may be added to rAAV vector preparations or administered separately to an individual in accordance with the methods and uses described in this application.
[0043] In certain embodiments, empty AAV capsids are formulated with rAAV vectors and / or administered to a mammal. In particular aspects, empty AAV capsids are formulated with a lesser or equal amount of vectors (e.g., about 1.0 to 100 times rAAV vectors to empty AAV capsids, or about 1:1 rAAV vectors). Petition 870260081961, dated 08 / 13 / 2026, page 169 / 305 14 / 69 for empty AAV capsids). In other particular aspects, rVAA vectors are formulated with an excess of empty AAV capsids (e.g., empty AAV capsids greater than 1 time for rAAV vectors, e.g., empty AAV capsids from 1.0 to 100 times for rAAV vectors). Optionally, a mammal with a low to negative AAV titer may receive lower amounts of empty capsids (1 to 10 times empty AAV capsids for rAAV vectors, 2-6 times empty AAV capsids for rAAV vectors, or about 4-5 times empty AAV capsids for rAAV vectors).
[0044] In certain embodiments, the vectors, methods, and uses of rAAV include an excess of empty capsids greater than the dose or quantity of rAAV vectors (i.e., those containing a nucleic acid encoding a therapeutic protein) in the composition. A ratio of empty capsids to rAAV vectors may be approximately 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10 to 1, or some other ratio.
[0045] In some embodiments, the empty capsids comprise the same VP1, VP2, and VP3 capsid proteins that are present in the rAAV vectors. In other embodiments, the empty capsids comprise VP1, VP2, and VP3 proteins with an amino acid sequence different from those found in the rAAV vectors. Optionally, if the capsid proteins of the capsids and empty capsids of the rAAV vectors are not identical in sequence, they will be of the same serotype.
[0046] In certain embodiments, empty capsids are included in vectors, methods, and uses of rAAV, where the rAAV vectors are in particular doses or quantities. In some embodiments, a dose of rAAV vectors is approximately 1x10¹⁰ to 1x10¹¹ g / kg of body weight. Petition 870260081961, dated 08 / 13 / 2026, pp. 170 / 305 15 / 69 mammal, or between approximately 1x1011a 1x1012vg / kg (for example, approximately 2x1011a to 3x1011vg / kg or approximately 3x1011 to 4x1011vg / kg or approximately 4x1011 to 5x1011vg / kg or approximately 5x1011 to 6x1011vg / kg or approximately 6x1011 to 7x1011vg / kg or approximately 7x1011 to 8x1011vg / kg or approximately 8x1011 to 9x1011vg / kg or approximately 9x1011 to 1x1012vg / kg) of the mammal's weight, or between approximately 1x1012a 1x1013 vg / kg of mammalian weight, and empty capsids.
[0047] In some embodiments, a dose or quantity of rAAV vector or a method or utilization using a dose or quantity of rAAV vector optionally has an excess of empty capsids. In some modalities, a dose of rAAV vectors is approximately 1x10¹⁰ to 1x10¹¹ vg / kg of mammalian weight, or between approximately 1x10¹¹ and 1x10¹² vg / kg (for example, approximately 1x10¹¹ to 2x10¹¹ vg / kg or approximately 2x10¹¹ to 3x10¹¹ vg / kg or approximately 3x10¹¹ to 4x10¹¹ vg / kg or approximately 4x10¹¹ to 5x10¹¹ vg / kg or approximately 5x10¹¹ to 6x10¹¹ vg / kg or approximately 6x10¹¹ to 7x10¹¹ vg / kg or approximately 7x10¹¹ to 8x10¹¹ vg / kg or approximately 8x10¹¹ to 9x10¹¹ vg / kg or approximately 9x10¹¹ to 1x10¹²vg / kg) of mammalian weight, or between approximately 1x10¹² to 1x10¹³vg / kg of mammalian weight, and an excess of empty capsids. The excess of capsids over each dose or quantity of rAAV vector can be approximately 1.5 to 100 times the empty capsids of AAV for rAAV vectors.If desired, the ratio of empty capsids to rVAA vectors can be approximately 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0. 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10 to 1.
[0048] In certain modalities, administration or delivery is by infusion or injection into the individual's systemic circulation. In certain modalities, administration or delivery is by intravenous or intra-arterial infusion or injection into the individual's systemic circulation. In certain Petition 870260081961, dated 08 / 13 / 2026, page 171 / 305 In 16 / 69 modalities, administration or delivery is by infusion or injection into the individual's hepatic portal vein. In certain modalities, administration or delivery is by an implant or pump that provides infusion or injection into the individual's systemic circulation, or that provides intravenous or intra-arterial infusion or injection into the individual's systemic circulation, or that provides infusion or injection into the individual's hepatic portal vein. Detailed Description
[0049] The invention is based, at least in part, on the development of an rAAV vector that, when administered to a non-central nervous system (CNS) or non-ocular cell, tissue or organ, is capable of infecting a non-central nervous system (CNS) or non-ocular target cells, tissues or organs for expression and providing subsequent delivery of the heterologous nucleic acid-encoded protein to the mammalian CNS or to an ocular cell, tissue or organ. Expression of the encoded protein by the non-central nervous system (CNS) or non-ocular cell, tissue or organ leads to secretion of the encoded protein into the systemic circulation which in turn delivers the encoded protein to the mammalian CNS and / or to the ocular cell, tissue or organ.Consequently, the invention provides methods for delivering proteins to the mammalian CNS and / or to the ocular cell, tissue, or organ without direct administration to the mammalian CNS and / or to the ocular cell, tissue, or organ, that is, to a cell, tissue, or organ other than the mammalian CNS or the ocular cell, tissue, or organ. Such target cells, tissues, and organs include endocrine cells, tissues, and organs. Particular, non-limiting examples include the liver (e.g., hepatocytes).
[0050] Adeno-associated virus (AAV) is a small, non-pathogenic virus of the parvoviridae family. AAV is distinct from other members of this family by its dependence on a helper virus for replication. In the absence of a helper virus, AAV can integrate specifically into the locus on the q arm of chromosome 19. The approximately 5 kb genome of AAV consists of a single-stranded DNA segment. Petition 870260081961, dated 08 / 13 / 2026, page 172 / 305 17 / 69 simple positive or negative polarity. The ends of the genome are small inverted terminal repeats that can fold into hairpin structures and serve as the origin of viral DNA replication. Physically, the parvovirus virion is non-enveloped and its icosahedral capsid is approximately 20-30 nm in diameter.
[0051] As will be appreciated by one skilled in the art, an AAV virion consists of three related proteins designated as VP1 protein and two shorter proteins, designated VP2 and VP3, which are essentially amino-terminal truncations of VP1. Depending on the capsid and other factors known to those skilled in the art, the three capsid proteins VP1, VP2, and VP3 are typically present in a capsid in an approximate ratio of 1:1:10, respectively, although this ratio, particularly of VP3, can vary significantly and should not be considered limiting in any respect.
[0052] The ends of the AAV genome have inverted terminal short repeats (ITRs) that have the potential to fold into T-shaped hook-like structures that serve as the origin of viral DNA replication. Within the ITR region, two elements central to ITR function have been described: a GAGC repeat motif and the terminal resolution site (trs). The repeat motif has been shown to bind to Rep when the ITR is in a linear or hook conformation. This binding serves to position Rep68 / 78 for cleavage at the trs, which occurs in a site- and strand-specific manner. In addition to their role in replication, these two elements appear to be central to viral integration. Contained within the chromosome 19 integration locus is a Rep binding site with an adjacent trs. These elements have been shown to be functional for locus-specific integration.
[0053] AAVs are useful as gene therapy vectors, since they can penetrate cells and introduce nucleic acid / genetic material, so that the nucleic acid / genetic material Petition 870260081961, dated 08 / 13 / 2026, page 173 / 305 18 / 69 can be stably maintained in cells. Furthermore, these viruses can introduce nucleic acid / genetic material into specific locations, for example. Because AAVs are not associated with pathogenic disease in humans, AAV vectors are capable of delivering heterologous polynucleotide sequences (e.g., proteins and therapeutic agents) to human patients without causing substantial AAV pathogenesis or disease.
[0054] Consequently, rVAA vectors, including serotypes and variants, provide a means for delivering nucleic acid sequences into cells ex vivo, in vitro, and in vivo, which may encode proteins, so that the cells express the encoded proteins. For example, a recombinant AAV vector may include a heterologous nucleic acid encoding a desired protein or peptide (e.g., a protective isoform of ApoE). Delivery or administration of vectors to an individual (e.g., mammal) therefore provides the encoded protein to the individual.
[0055] As used in this application, the term recombinant, as a modifier of AAV vectors, as well as a modifier of sequences such as recombinant polypeptides and nucleic acids, means that the compositions (e.g., AAVs or sequences) have been manipulated (i.e., engineered) in a manner that does not generally occur in nature. A particular example of a recombinant AAV vector would be when a nucleic acid that is not normally present in the viral genome (e.g., wild-type AAV (“heterologous”) is inserted into the viral genome. A “recombinant” AAV vector is distinguished from an AAV genome since all or part of the viral genome has been replaced by a non-native sequence relative to the AAV genomic nucleic acid, such as with a heterologous nucleic acid sequence.Although the term recombinant is not always used here in reference to AAV vectors, as well as sequences such as nucleic acids and polypeptides, recombinant forms of AAV, and sequences including nucleic acids and... Petition 870260081961, dated 08 / 13 / 2026, pp. 174 / 305 19 / 69 polypeptides are expressly included despite any omissions.
[0056] Typically, for AAV, one or both of the inverted terminal repeat (ITR) sequences of the AAV genome are retained in the AAV vector. The incorporation of a non-native sequence (e.g., ApoE guard isoform) therefore defines the AAV vector as a “recombinant” AAV vector (rAAV).
[0057] A recombinant AAV vector may be packaged—referred to in this application as a “particle”—for subsequent infection (transduction) of a cell, ex vivo, in vitro, or in vivo. When a recombinant AAV vector sequence is encapsulated or packaged into an AAV particle, the particle may also be referred to as a “rAAV.” Such particles include proteins that encapsulate or package the vector genomes and, in the case of AAVs, capsid proteins.
[0058] An “AAV viral particle” or “AAV particle” refers to a viral particle composed of at least one AAV capsid protein (typically all the capsid proteins of an AAV) and an encapsulated nucleic acid, referred to as a vector genome. If the particle comprises heterologous nucleic acid, it is typically referred to as a “rAAV”.
[0059] An AAV vector “genome” refers to the portion of the recombinant plasmid sequence that is ultimately packaged or encapsulated to form an AAV particle. In cases where recombinant plasmids are used to construct or manufacture recombinant AAV vectors, the AAV vector genome does not include the portion of the plasmid that does not correspond to the recombinant plasmid vector genome sequence. This non-vector portion of the recombinant plasmid genome is referred to as the “plasmid structure,” which is important for plasmid cloning and amplification, a process that is necessary for the propagation and production of recombinant AAVs, but is not packaged or encapsulated into rAAV particles. Petition 870260081961, dated 08 / 13 / 2026, pages 175 / 305 20 / 69
[0060] In particular embodiments, rAAV vectors include capsids derived from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rh10, Rh74 and AAV-2i8, as well as variants (e.g., capsid variants such as amino acid insertions, additions and substitutions). rAAV vector serotypes and variants include capsid variants (e.g., LK03, 4-1, etc.).
[0061] rAAV serotypes and rAAV variants (e.g., capsid variants such as LK03, 4-1) may or may not be distinct from other AAV serotypes (e.g., distinct from VP1, VP2, and / or VP3 sequences). As used herein, the term “serotype” is a distinction used to refer to an AAV having a capsid that is serologically distinct from other AAV serotypes. Serological distinction is determined based on the lack of cross-reactivity between antibodies to one AAV compared to another AAV. These cross-reactivity differences are generally due to differences in capsid protein sequences / antigenic determinants (e.g., due to differences in VP1, VP2, and / or VP3 sequences of AAV serotypes).Although AAV variants that include capsid variants may not be serologically distinct from a reference AAV or another AAV serotype, they differ in at least one nucleotide or amino acid residue compared to the reference or other AAV serotype.
[0062] According to the traditional definition, a serotype means that the virus of interest has been tested in specific serum for all existing serotypes and characterized for neutralizing activity, and no antibodies have been found that neutralize the virus of interest. As more isolates of naturally occurring viruses are discovered and / or capsid mutants are generated, there may or may not be serological differences with any of the currently existing serotypes. Therefore, in cases where the new virus (e.g., AAV) has no serological difference, this new virus (e.g., AAV) would be a subgroup or variant of the corresponding serotype. Petition 870260081961, dated 08 / 13 / 2026, page 176 / 305 21 / 69 In many cases, serological testing for neutralizing activity has not yet been performed on mutant viruses with capsid sequence modifications to determine whether they are of a different serotype according to the traditional definition of serotype. Therefore, for convenience and to avoid repetition, the term "serotype" broadly refers to both serologically distinct viruses (e.g., AAV) as well as viruses (e.g., AAV) that are not serologically distinct but may be within a subgroup or variant of a given serotype.
[0063] Recombinant AAV vectors (e.g., rAAV), as well as their methods and uses, include any viral strain or serotype. As a non-limiting example, a recombinant AAV vector genome can be based on any AAV genome, such as AAV-1, -2, -3, -4, -5, -6, -7, -8, -9, -10, -11, -rh74, -rh10, or AAV-2i8, for example. Such vectors may be based on the same strain or serotype (or subgroup or variant), or be different from each other. As a non-limiting example, a recombinant AAV vector genome based on a serotype genome may be identical to one or more of the capsid proteins that package the vector.Furthermore, a recombinant AAV vector genome can be based on an AAV serotype genome (e.g., AAV2) distinct from one or more of the capsid proteins that package the vector, in which case at least one of the three capsid proteins can be AAV1, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rh10, Rh74 or AAV-2i8 or variants (e.g., capsid variants such as LK03, 4-1, etc.), for example.
[0064] AAV vectors therefore include gene / protein sequences identical to the gene / protein sequences characteristic of a particular serotype. As used in this application, an “AAV1-related AAV vector” refers to one or more AAV proteins (e.g., VP1, VP2, and / or VP3 sequences) that have substantial sequence identity with one or more polynucleotide or polypeptide sequences comprising AAV1. Analogously, an “AAV vector Petition 870260081961, dated 08 / 13 / 2026, p. 177 / 305 "22 / 69 related to AAV8" refers to one or more AAV proteins (e.g., VP1, VP2, and / or VP3 sequences) that have substantial sequence identity with one or more polynucleotide or polypeptide sequences comprising AAV8. An "AAVRh74-related AAV vector" refers to one or more AAV proteins (e.g., VP1, VP2, and / or VP3 sequences) that have substantial sequence identity with one or more polynucleotide or polypeptide sequences comprising AAV-Rh74.Such AAV vectors related to another serotype, for example, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rh10, Rh74, or AAV-2i8, may therefore have one or more distinct sequences from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rh10, Rh74, and AAV-2i8, but may exhibit substantial sequence identity for one or more genes and / or proteins, and / or have one or more functional characteristics of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rh10, Rh74, or AAV-2i8 (for example). , such as cell / tissue tropism). Examples of non-limiting Rh74 AAVs and related AAV variants include the 4-1 capsid variant in Example 6.
[0065] In several exemplary embodiments, an AAV vector related to a reference serotype has a polynucleotide, polypeptide, or subsequence thereof that includes or consists of a sequence that is at least 70% or more (e.g., 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, etc.) identical to one or more AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rh10, Rh74, or AAV-2i8. Consequently, the methods and uses of the invention include AAV (polypeptide and nucleotide) sequences and their subsequences that exhibit 100% or less than 100% sequence identity with a reference AAV serotype such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rh10 or AAV-2i8, for example, the AAV-Rh74 gene or protein sequence (e.g., VP1, VP2). Petition 870260081961, dated 08 / 13 / 2026, pp. 178 / 305 23 / 69 and / or VP3 shown in Example 6), but they may be distinct from, and not identical to, known AAV genes or proteins, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rh10, Rh74 or AAV-2i8 genes or proteins, etc.
[0066] In one embodiment, an AAV polypeptide or its subsequence includes or consists of a sequence that is at least 70% or more identical, for example, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%. , 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, etc., that is, up to 100% identical to any AAV reference sequence or subsequence thereof, such as AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, Rh10, Rh74 or AAV-2i8 (for example, VP1, VP2 and / or VP3 shown in Example 6). In particular aspects, an AAV variant comprises a 4-1 capsid variant or LK03 VP1, VP2, and / or VP3 as set forth in Example 6. Recombinant AAV vectors, and chimeric, hybrid, and variant sequences can be constructed using recombinant techniques known to those skilled in the art, to include one or more heterologous nucleic acid sequences (transgenes) flanked with one or more functional AAV ITR sequences.Such rAAV vectors may possess one or more of the wild-type AAV genes, eliminated in whole or in part, for example, a rep and / or cap gene, but retain at least one functional flanking ITR sequence, as required for salvage, replication, and packaging of the recombinant vector into an AAV vector particle. An AAV vector genome would therefore include sequences required in cis for replication and packaging (e.g., functional ITR sequences).
[0067] An “AAV ITR” or “AAV ITRs” refers to the technically recognized regions found at each end of the AAV genome that function together in cis as origins of DNA replication and as packaging signals for the virus. AAV ITRs, along with the AAV rep coding region, provide excision. Petition 870260081961, dated 08 / 13 / 2026, page 179 / 305 24 / 69 efficient and the recovery and integration of a nucleotide sequence interposed between two flanking ITRs in a mammalian cell genome.
[0068] The nucleotide sequences of AAV ITRs are known. An “AAV ITR” does not need to have the described wild-type nucleotide sequence, but can be altered, for example, by insertion, deletion, or substitution of nucleotides. Additionally, the AAV ITR can be derived from any of several AAV serotypes. Furthermore, the 5' and 3' ITRs flanking a heterologous nucleic acid sequence in an AAV vector do not necessarily need to be identical or derived from the same AAV serotype or isolate, as long as they function as intended, i.e., to allow excision and rescue of the sequence of interest from the host cell genome or vector and to allow integration of the heterologous sequence into the recipient cell genome.
[0069] The terms “nucleic acid” and “polynucleotide” are used interchangeably to refer to all forms of nucleic acid, oligonucleotides, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Polynucleotides include genomic DNA, cDNA and antisense DNA, and processed or unprocessed mRNA, tRNA, and inhibitory DNA or RNA (RNAI, for example, small or short hook (sh)RNA, microRNA (miRNA), small or short interfering (si)RNA, transjunction RNA or antisense RNA). Nucleic acids include naturally occurring, synthetic, and intentionally modified or altered polynucleotides (e.g., having reduced CpG dinucleotides). Nucleic acids can be single, double, or triple, linear or circular. When discussing nucleic acids, the sequence or structure of a particular nucleic acid can be described here according to the convention of providing the sequence in the 5' to 3' direction.
[0070] The rAAV vectors as presented here comprise an exogenous (heterologous) nucleic acid functionally linked to Petition 870260081961, dated 08 / 13 / 2026, pp. 180 / 305 25 / 69 a promoter. A “heterologous” nucleic acid refers to a nucleic acid inserted into an AAV vector for the purpose of transferring / delivering the nucleic acid into a cell, tissue, or organ. Heterologous nucleic acids are distinct from the AAV nucleic acid, i.e., they are not native to the AAV nucleic acid. For example, in certain embodiments, the heterologous nucleic acid encodes a protective isoform of ApoE.
[0071] Although the term heterologous is not always used here in reference to nucleic acid, the reference to a nucleic acid, even in the absence of the heterologous modifier, is intended to include heterologous nucleic acids, despite the omission. Once transferred / delivered into the cell, a heterologous nucleic acid, contained within the rAAV vector, can be expressed (e.g., transcribed and translated, if appropriate).
[0072] The term transgene is used here to conveniently refer to a heterologous nucleic acid that is intended for, or has been introduced into, a cell or organism. Transgenes include any nucleic acid, such as a gene that codes for a polypeptide or a protein (e.g., a protective isoform of apoE).
[0073] In a cell possessing a transgene, the transgene has been introduced / transferred by means of a “transduction” or “infection” of an rAAV vector into the cell. The terms “infect” and “transduce” refer to the introduction of a molecule, such as a nucleic acid, into a host cell (e.g., HEK293) or cells from an AAV vector. A “transduced” or “infected” cell (e.g., in a mammal, such as a cell or tissue or organ cell) is a genetic alteration in a cell following the incorporation of a nucleic acid (e.g., a transgene) into the cell. Therefore, a “transduced” or “infected” cell is a cell into which, or a progeny thereof into which, an exogenous nucleic acid has been introduced. The cell(s) can be propagated and the introduced nucleic acid transcribed and the protein expressed. For gene therapy uses and methods, a cell Petition 870260081961, dated 08 / 13 / 2026, pp. 181 / 305 26 / 69 transduced may be in an individual.
[0074] Cells that can be transduced include non-CNS cells, tissues, or organs. CNS cells, tissues, or organs include cerebrospinal fluid (CSF), the brain, the intracranial space, and the spinal cord. Thus, reference to non-CNS cells, tissues, or organs excludes cerebrospinal fluid (CSF), the brain, the intracranial space, and the spinal cord.
[0075] Cells that can be transduced also include non-ocular cells, tissues, or organs. Ocular cells, tissues, and organs include the eye and parts of the eye. Thus, reference to non-ocular cells, tissues, or organs excludes the eye and parts of the eye.
[0076] Non-limiting examples of non-CNS and non-ocular cells include liver (e.g., hepatocytes, sinusoidal endothelial cells) and pancreas (e.g., beta islet cells). Other examples include skeletal muscle cells (e.g., fibroblasts).
[0077] The “polypeptides”, “proteins” and “peptides” encoded by the “nucleic acid sequence” include native full-length sequences, as with naturally occurring proteins, as well as functional subsequences, modified forms or variant sequences, provided that the subsequence, modified form or variant retains some degree of functionality of the entire native protein. In methods and uses of the invention, proteins and peptides encoded by the nucleic acid sequences may be, but need not be, identical to the endogenous protein that is defective, or whose expression is insufficient, or deficient in the treated mammal.
[0078] A “therapeutic molecule,” in one embodiment, is a peptide or protein that can alleviate or reduce symptoms resulting from an absence or defect of a protein in a cell or individual. Alternatively, a therapeutic protein or peptide encoded by a transgene may confer a benefit to an individual, for example, to correct a genetic defect, to correct a deficiency in the gene (expression or Petition 870260081961, dated 08 / 13 / 2026, pp. 182 / 305 27 / 69 functional), etc.
[0079] Non-limiting examples of heterologous nucleic acids encoding useful therapeutic proteins according to the invention include those that can be used in the treatment of a disease or disorder including, but not limited to, a disease or disorder of the CNS. Particular non-limiting examples include a protective isoform of ApoE, for example, a sequence at least 70% identical to human ApoE ε2; TPP1, for example, a sequence at least 70% identical to human TPP1; CLN3, for example, a sequence at least 70% identical to human CLN3; PPT1, for example, a sequence at least 70% identical to human PPT1; CLN6, for example, a sequence at least 70% identical to human CLN6; and CLN8, for example, a sequence at least 70% identical to human CLN8.Other specific, non-limiting examples include galactosamine-6-sulfatase, for example, a sequence at least 70% identical to human galactosamine-6-sulfatase, and beta-glucuronidase, for example, a sequence at least 70% identical to human beta-glucuronidase.
[0080] Non-limiting examples of a CNS disease or disorder include Alzheimer's disease, a lysosomal storage disease, neuronal ceroid lipofuscinosis (NCL), such as infantile NCL, late-onset infantile NCL, juvenile NCL (Batten disease), adult NCL, or mucopolysaccharidosis (e.g., MPS IV or MPS VII).
[0081] The rAAV vectors as presented here optionally include additional elements such as an expression control element (e.g., a promoter, enhancer), intron, ITR(s), poly-adenine sequence (also referred to as polyadenylation). An “expression control element” refers to sequence(s) that influence the expression of an operationally linked nucleic acid. Control elements, including expression control elements as presented here, such as promoters and enhancers, present in a Petition 870260081961, dated 08 / 13 / 2026, pp. 183 / 305 28 / 69 vectors are included to facilitate proper heterologous nucleic acid transcription and, if appropriate, translation (e.g., a promoter, enhancer, signal processing for introns, maintenance of the correct gene reading frame to allow translation into mRNA frame and stop codons, etc.). Such elements typically act in cis, referred to as a cis-acting element, but can also act in trans.
[0082] Expression control can be effected at the level of transcription, translation, joining, message stability, etc. Typically, an expression control element that modulates transcription is juxtaposed near the 5' end (i.e., upstream) of a transcribed nucleic acid. Expression control elements can also be located at the 3' end (i.e., “downstream”) of the transcribed sequence or within the transcript (e.g., in an intron). Expression control elements can be located adjacent to or distant from the transcribed sequence (e.g., 1-10, 10-25, 25-50, 50-100, 100 to 500 or more nucleotides of the polynucleotide), even at considerable distances. However, due to the length limitations of certain vectors, such as AAV vectors, these expression control elements will typically be within 1 to 1000 nucleotides of the transcribed nucleic acid.
[0083] Functionally, the expression of operationally linked heterologous nucleic acid is, at least in part, controllable by the element (e.g., promoter) such that the element modulates the transcription of the polynucleotide and, as appropriate, the transformation of the transcript. A specific example of an expression control element is a promoter, which is usually located 5' from the transcript sequence. Another example of an expression control element is an enhancer, which may be located 5', 3' from the transcript sequence, or within the transcript sequence.
[0084] A promoter as used herein may refer to a nucleic acid sequence (e.g., DNA) that is located Petition 870260081961, dated 08 / 13 / 2026, pp. 184 / 305 29 / 69 adjacent to a polynucleotide sequence that codes for a recombinant product. A promoter is typically operationally linked to an adjacent sequence, for example, heterologous nucleic acid. A promoter typically increases the amount expressed of a heterologous polynucleotide compared to the amount expressed when no promoter is present.
[0085] An “enhancer” as used herein may refer to a sequence that is located adjacent to the heterologous polynucleotide. Enhancer elements are typically located upstream of a promoter element, but they also function and may be located downstream or within a DNA sequence (e.g., a heterologous nucleic acid). Therefore, an enhancer element may be located 100 base pairs, 200 base pairs, or 300 or more base pairs upstream or downstream of a heterologous nucleic acid. Enhancer elements typically augment a heterologous nucleic acid upstream by an expression achieved by a promoter element.
[0086] Expression control elements (e.g., promoters) include those active in a particular tissue or cell type, referred to herein as “tissue-specific expression control elements / promoters.” Tissue-specific expression control elements are typically active in specific cells or tissues (e.g., liver, pancreas, muscle, etc.). Expression control elements are typically active in these cells, tissues, or organs because they are recognized by transcriptional activator proteins, or other regulators of transcription, that are unique to a specific cell, tissue, or organ type.
[0087] The promoter can be any desired promoter, selected based on known considerations, such as the expression level of a nucleic acid functionally linked to the promoter and the cell type in which the vector is to be used. Promoters can be an exogenous promoter. Petition 870260081961, dated 08 / 13 / 2026, pages 185 / 305 30 / 69 or endogenous.
[0088] Examples of active promoters in skeletal muscle include promoters of genes encoding skeletal α-actin, myosin light chain 2A, dystrophin, muscle creatine kinase, as well as synthetic muscle promoters with activities superior to naturally occurring promoters (see, for example, Li, et al., Nat. Biotech. 17:241-245 (1999)). Examples of promoters that are tissue-specific for the liver are the human alpha 1-antitrypsin (hAAT) promoter; albumin, Miyatake, et al. J. Virol. 71:5124-32 (1997); hepatitis B virus core promoter, Sandig, et al., Gene Ther. 3:1002-9 (1996); alpha-fetoprotein (AFP), Arbuthnot, et al., Hum. Gene. Ther., 7:1503-14 (1996)], bone (osteocalcin, Stein, et al., Mol. Biol. Rep., 24:185-96 (1997); bone sialoprotein, Chen, et al., J. Bone Miner. Res. 11:654-64 (1996)), lymphocytes (CD2, Hansal, et al., J. Immunol., 161:1063-8 (1998); immunoglobulin heavy chain; T cell receptor alpha chain) and TTR promoter. An example of an active enhancer in the liver is apolipoprotein E (apoE) HCR-1 and HCR-2 (Allan et al., J. Biol. Chem., 272:29113-19 (1997)).
[0089] Expression control elements also include ubiquitous or promiscuous promoters / enhancers that are capable of directing the expression of a polynucleotide in many different cell types. These elements include, but are not limited to, viral promoters such as the immediate cytomegalovirus (CMV) promoter / enhancer sequences, the Rous sarcoma virus (RSV) promoter / enhancer sequences, and other viral promoters / enhancers active in a variety of mammalian cell types or synthetic elements not present in nature (see, for example, Boshart et al., Cel., 41:521-530 (1985)), the SV40 promoter, the bovine papillomavirus promoter, the dihydrofolate reductase promoter, the cytoplasmic β-actin promoter, and the phosphoglycerol kinase (PGK) promoter. Additional promoters include the inducible promoter of Petition 870260081961, dated 08 / 13 / 2026, pp. 186 / 305 31 / 69 metallothionein, an AAV promoter, such as an AAV p5 promoter, actin gene-derived promoters, immunoglobulin genes, adenoviral promoters, such as the adenoviral late major promoter, an inducible heat shock promoter, respiratory syncytial virus, etc.
[0090] Expression control elements can also confer expression in a regulable manner, i.e., a signal or stimulus increases or decreases the expression of the operationally linked heterologous polynucleotide. A regulable element that increases the expression of the operationally linked polynucleotide in response to a signal or stimulus is also referred to as an inducible element (i.e., it is induced by a signal). Particular examples include, but are not limited to, an inducible hormone promoter (e.g., steroid). A regulable element that decreases the expression of the operationally linked polynucleotide in response to a signal or stimulus is referred to as a repressible element (i.e., the signal decreases expression such that when the signal is removed or absent, expression is increased).Typically, the amount of increase or decrease conferred by such elements is proportional to the amount of signal or stimuli present; the greater the amount of signal or stimulus, the greater the increase or decrease in expression. Particular, but not limiting, examples include the zinc-inducible sheep metallothionein promoter (MT); the steroid hormone-inducible mouse mammalian tumor virus (MMTV) promoter; the T7 polymerase promoter system (WO 98 / 10088); the tetracycline-inducible system (Gossen, et al., Proc. Natl. Acad. Sci. USA, 89:55475551 (1992)); the tetracycline-inducible system (Gossen, et al., Science. 268:1766-1769 (1995); see also Harvey, et al., Curr. Opinion. Chem. Biol. 2:512-518 (1998)); the RU486-inducible system (Wang, et al., Nat. Biotech. 15:239-243 (1997) and Wang, et al., Gene Ther. 4:432-441 (1997)]; and the rapamycin-inducible system (Magari, et al., J. Clin. Invest. 100:2865-2872 (1997); Rivera et al. Petition 870260081961, dated 08 / 13 / 2026, pp. 187 / 305 32 / 69 regulated by a specific physiological state, for example, temperature, acute phase, development.
[0091] As used in this application, the term “operable linkage” or “operationally linked” refers to a physical or functional juxtaposition of the components thus described so as to enable them to function in the intended manner. In the example of an expression control element in operable linkage with a nucleic acid, the relationship is such that the control element modulates the expression of the nucleic acid. More specifically, for example, two operationally linked DNA sequences means that the two DNAs are arranged (cis or trans) in a relationship such that at least one of the DNA sequences is capable of exerting a physiological effect on the other sequence.
[0092] Additional elements that rAAV vectors and plasmids include, for example, polynucleotide filler or packing sequences, for example, to improve packaging and reduce the presence of contaminating nucleic acid, for example, to reduce packing of the plasmid main strand. AAV vectors typically accept DNA inserts having a defined size range that is generally from about 4 kb to about 5.2 kb, or slightly more. Therefore, for shorter sequences, the inclusion of a filler in the insert fragment in order to adjust the length to near or to the normal size of the virus genomic sequence acceptable for packaging the AAV vector into virus particles. In several embodiments, a filler / packer nucleic acid sequence is a segment of untranslated nucleic acid (non-protein coding).In particular embodiments of an AAV vector, a heterologous polynucleotide sequence has a length of less than 4.7 Kb, the filler or padding heterologous polynucleotide sequence has a length that when combined (e.g., inserted into a vector) with the sequence has a total length between about 3.0-5.5 Kb, or thereabouts. Petition 870260081961, dated 08 / 13 / 2026, pages 188 / 305 33 / 69 about 4.0-5.0 Kb, or between about 4.3-4.8 Kb.
[0093] The “empty capsids” of AAV, as used herein, do not contain a vector genome (hence the term “empty”), in contrast to “genome-containing capsids,” which contain an AAV vector genome. Empty capsids are virus-like particles in that they react with one or more antibodies that react with the intact virus (genome-containing AAV vector).
[0094] Although not wanting to be limited by theory, it is believed that empty AAV capsids bind to or react with antibodies against AAV vectors, thus functioning as a decoy to reduce AAV vector inactivation. This decoy acts to absorb antibodies directed against the AAV vector, thus increasing or improving the transduction of the AAV vector transgene into cells (transgene introduction) and, in turn, increases the cellular expression of the encoded transcript and / or protein.
[0095] Empty capsids can be generated and purified to a determined quality and quantity. For example, the empty capsid titer can be measured by optical density spectrophotometry at a wavelength of 280 nm (based on Sommer et al., Mol. Ther. 2003 Jan; 7 (1): 122-8).
[0096] Empty AVVs or empty capsids are sometimes found naturally in AAV vector preparations. Such natural mixtures can be used according to the invention or, if desired, can be manipulated to increase or decrease the amount of empty capsid and / or vector. For example, the amount of empty capsid can optionally be adjusted to an amount that would be expected to reduce the inhibitory effect of antibodies reacting with an AAV vector intended for use in vector-mediated gene transduction in an individual. The use of empty capsids is described in US publication 2014 / 0336245.
[0097] In several embodiments, empty AAV capsids are formulated with rAAV vectors and / or administered to an individual. In Petition 870260081961, dated 08 / 13 / 2026, pp. 189 / 305 34 / 69 particular aspects, empty AAV capsids are formulated with a lesser or equal number of vectors (e.g., approximately 1.0 to 100 times the number of AAV vectors for empty AAV capsids, or approximately 1:1 of AAV vectors for empty AAV capsids). In other particular aspects, VAA vectors are formulated with an excess of empty AAV capsids (e.g., more than 1 to 100 times the number of empty AAV capsids for AAV vectors, e.g., 1.0 to 100 times the number of empty AAV capsids for AAV vectors).
[0098] In some embodiments, the empty capsids comprise the same VP1, VP2, and VP3 capsid proteins that are present in the rAAV vectors. In other embodiments, the empty capsids comprise VP1, VP2, and VP3 proteins with a different amino acid sequence than those found in the rAAV vectors. Typically, though not necessarily, if the capsid proteins of the empty capsids and the capsids of the rAAV vectors are not identical in sequence, they will be of the same serotype.
[0099] Suitable mammals include humans, non-human primates (monkeys, gibbons, gorillas, chimpanzees, orangutans, apes), a domestic animal (dogs and cats), a farm animal (domestic fowl such as chickens and ducks, horses, cows, goats, sheep, pigs), and experimental animals (mouse, rat, rabbit, guinea pig). Humans include fetal, neonatal, infant, juvenile, and adult subjects. Animal disease models include, for example, mouse models and other mammalian models known to those skilled in the art.
[0100] A mammal suitable for treatment includes those that have or are at risk of producing an insufficient quantity of, or have a deficiency in, a functional gene product (protein), or produce an aberrant, partially functional or non-functional gene product (protein) that may lead to disease. Individuals suitable for treatment according to the invention also include those that have or are at risk of producing a Petition 870260081961, dated 08 / 13 / 2026, pp. 190 / 305 35 / 69 an aberrant or deficient (mutant) genetic product (protein) that leads to a disease such that reducing the amounts, expression, or function of the aberrant or defective mutant genetic product (protein) would lead to treatment of the disease, or reduce one or more symptoms, or improve the disease.
[00100] Consequently, the mammal may have a condition that is amenable to gene replacement therapy. As used in the present application, “gene replacement therapy” refers to the administration to the recipient of nucleic acid encoding a protein and subsequent expression of the administered nucleic acid in situ. Thus, the phrase “condition amenable to gene replacement therapy” encompasses conditions such as genetic diseases (i.e., a disease condition that is attributable to one or more genetic defects). According to one embodiment, the mammalian recipient has a genetic disease and the rAAV vector comprises a heterologous nucleic acid encoding a therapeutic protein for the treatment of the disease.
[0101] The invention provides methods for delivering a nucleic acid to a non-CNS cell, tissue or organ and methods for delivering a nucleic acid to a non-ocular cell, tissue or organ comprising administering to the cell, tissue or organ an rAAV particle containing a vector comprising the nucleic acid inserted between a pair of inverted terminal repeats of AAV, thereby delivering the nucleic acid to the cell, tissue or organ. The rAAV particle may remain in contact with the cells for any desired period of time, and typically the particle is administered and left to remain indefinitely. Administration to the cell may be performed by any means, including local or regional, or systemic, provided that it is not administered to the CNS and / or to ocular cells, tissues or organs.
[0102] The rAAV vector may comprise a heterologous nucleic acid encoding an ApoE protective isoform protein. The rAAV vector infects non-CNS and / or non-ocular cells, and the ApoE protective isoform protein is expressed and secreted. The protein of Petition 870260081961, dated 08 / 13 / 2026, pp. 191 / 305 36 / 69 The protective isoform of ApoE, once expressed and secreted, enters the circulation and, in turn, enters the CNS.
[0103] rAAV expression vectors can be constructed using known techniques to at least provide, as operatively linked components in the direction of transcription, control elements including a transcription initiation region, the DNA of interest, and a transcription termination region. The control elements are selected to be functional in a mammalian cell. The resulting construct containing the operatively linked components is flanked (5' and 3') with functional ITR AAV sequences.
[0104] To produce rAAV virions, an AAV expression vector is introduced into a suitable host cell using known techniques, such as transfection. Several transfection techniques are generally known in the art. See, for example, Samulski et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York. Particularly suitable transfection methods include co-precipitation with calcium phosphate, direct microinjection into cultured cells, electroporation, liposome-mediated gene transfer, lipid-mediated transduction, and nucleic acid delivery using high-velocity microprojectiles.
[0105] The “AAV rep coding region” refers to the region of the AAV genome that encodes the replication proteins Rep 78, Rep 68, Rep 52, and Rep 40. Rep expression products have many functions, including binding to and cutting the AAV origin of DNA replication; DNA helicase activity; and modulation of transcription from AAV (or other heterologous) promoters. Rep expression products are collectively required to replicate the AAV genome. Suitable homologs of the AAV rep coding region include the rep gene of human herpesvirus 6 (HHV-6), which is also known to mediate AAV2 DNA replication.
[0106] The auxiliary functions of AAV can be Petition 870260081961, dated 08 / 13 / 2026, pp. 192 / 305 37 / 69 introduced into a host cell through transfection of the host cell with an AAV helper construct prior to or concurrently with transfection of the AAV expression vector. AAV helper constructs are therefore used to provide at least transient expression of AVV rep and / or cap genes to supplement the missing AAV functions that are necessary to produce AAV infection. AAV helper constructs do not possess AAV ITRs and cannot replicate or package themselves. These constructs may be in the form of a plasmid, phage, transposon, cosmid, virus, or virion. Several AAV helper constructs have been described, such as the pAAV / Ad and pIM29+45 plasmids that encode both Rep and Cap expression products. Several other vectors have been described that encode Rep and / or Cap expression products.
[0107] The rAAV vectors of the invention, compositions, agents, drugs, biological products (proteins) can be incorporated into pharmaceutical compositions, for example, a pharmaceutically acceptable vehicle or excipient. Such pharmaceutical compositions are useful for, among other things, administration and delivery to an individual in vivo.
[0108] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as that normally understood by a person skilled in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein may be used in the practice or testing of this invention, suitable methods and materials are described herein.
[0109] All applications, publications, patents and other references, GenBank citations and ATCC citations cited herein are incorporated by reference in their entirety. In case of conflict, the descriptive report, including definitions, will control.
[0110] All features disclosed here can be combined in any combination. Each feature disclosed in the descriptive report can be replaced by an alternative feature. Petition 870260081961, dated 08 / 13 / 2026, pp. 193 / 305 38 / 69 serving the same, equivalent, or similar purpose. Therefore, unless expressly indicated otherwise, the disclosed features (e.g., nucleic acid vector, vector, plasmid, a recombinant AAV vector (rAAV), vector genome, or rAAV virus particle) are an example of a genus of equivalent or similar features.
[0111] As used in this application, the terms “pharmaceutically acceptable” and “physiologically acceptable” mean a biologically acceptable gaseous, liquid or solid formulation, or a mixture thereof, that is suitable for one or more routes of administration, delivery or in vivo contact. A “pharmaceutically acceptable” or “physiologically acceptable” composition is a material that is not biologically or otherwise undesirable, for example, the material can be administered to an individual without causing substantial undesirable biological effects. Thus, such a pharmaceutical composition can be used, for example, in the administration of an rAAV vector or rAAV particle to an individual.
[0112] Such compositions include solvents (aqueous or non-aqueous), solutions (aqueous or non-aqueous), emulsions (e.g., oil-in-water or water-in-oil), suspensions, syrups, elixirs, dispersing and suspending media, coatings, isotonics, and absorption-promoting or retarding agents, compatible with pharmaceutical administration or in vivo contact or delivery. Aqueous and non-aqueous solvents, solutions, and suspensions may include suspending agents and thickening agents. Pharmaceutically acceptable vehicles include tablets (coated or uncoated), capsules (hard or soft), micropearls, powder, granules, and crystals. Additional active compounds (e.g., preservatives, antibacterial, antiviral, and antifungal agents) may also be incorporated into the compositions.
[0113] Pharmaceutical compositions include vehicles, diluents or excipients suitable for administration by various routes. Compositions suitable for parenteral administration comprise Petition 870260081961, dated 08 / 13 / 2026, pp. 194 / 305 39 / 69 Aqueous and non-aqueous solutions, suspensions, or emulsions of the active compound, preparations that are typically sterile and may be isotonic with the blood of the intended recipient. Illustrative but not limiting examples include water, saline solution, dextrose, fructose, ethanol, animal, vegetable, or synthetic oils.
[0114] Pharmaceutical compositions and delivery systems suitable for the compositions, methods and uses of the invention are known in the art (see, for example, Remington: The Science and Practice of Pharmacy (2003) 20th ed., Mack Publishing Co., Easton, PA; Remington's Pharmaceutical Sciences (1990) 18th ed., Mack Publishing Co., Easton, PA; The Merck Index (1996) 12th ed., Merck Publishing Group, Whitehouse, NJ; Pharmaceutical Principles of Solid Dosage Forms (1993), Technonic Publishing Co., Inc., Lancaster, Pa.; Ansel and Stoklosa, Pharmaceutical Calculations (2001) 11th ed., Lippincott Williams & Wilkins, Baltimore, MD; and Poznansky et al., Drug Delivery Systems (1980), RL Juliano, ed., Oxford, NY, pp. 253-315).
[0115] A “unit dose” or a “unit dosage form,” as used herein, refers to physically discrete units suitable as unit dosages for the individual to be treated; each unit containing a predetermined amount optionally in association with a pharmaceutical vehicle (excipient, diluent, carrier or filler) which, when administered in one or more doses, is calculated to produce a desired effect (e.g., prophylactic or therapeutic effect). Unit dosage forms may be contained within, for example, ampoules and vials, which may contain a liquid composition, or a composition in a lyophilized or freeze-dried state; a sterile liquid vehicle, for example, may be added prior to in vivo administration or delivery. Individual unit dosage forms may be included in multi-dose kits or containers. rAAV vectors, rAAV particles and their pharmaceutical compositions may be packaged in dosage form. Petition 870260081961, dated 08 / 13 / 2026, pp. 195 / 305 40 / 69 single or multiple packs for ease of administration and dosage uniformity.
[0116] A variety of detection methods can be used to determine the state of a disease or improvement. Such detection methods include immunodetection. Immunodetection methods include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoradiometric assay, fluoroimmunoassay, chemiluminescent assay, bioluminescent assay, and Western blot. Others are known for those of common skill. Several useful immunodetection methods have been described in the scientific literature.
[0117] In general, immunologic ligation methods involve obtaining a sample suspected of containing Aβ protein and contacting the sample with a first antibody, monoclonal or polyclonal specific for Aβ, as appropriate, under conditions effective in allowing the formation of immune complexes.
[0118] Immunoligation methods include methods for detecting and / or quantifying the amount of Aβ protein in a sample and the detection and / or quantification of any immune complexes formed during the ligation process. Here, one can obtain a sample suspected of containing Aβ protein, and contact the sample with an antibody and then detect and quantify the amount of immune complexes formed under specific conditions.
[0119] Contacting a biological sample with an antibody under conditions and for a period of time sufficient to allow the formation of immune complexes (primary immune complexes) is generally a matter of simply adding the antibody composition to the sample and incubating the mixture for a period of time so that the antibodies form immune complexes with, i.e., bind to any antigens present. After this period, the sample, such as blood, plasma, or serum samples, or a Petition 870260081961, dated 08 / 13 / 2026, pages 196 / 305 41 / 69 Tissue section, ELISA plate, dot blot, or western blot, will generally be processed (e.g., washed) to remove any non-specifically bound antibody species, allowing only the specifically bound molecules within the primary immune complexes to be detected.
[0120] In general, the detection of immune complex formation is known in the art and can be achieved through the application of numerous approaches. These methods are generally based on the detection of a marker or label, such as any of these radioactive, fluorescent, biological, and enzymatic markers. US patents on the use of such labels include Pat. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241. Naturally, one can employ the use of a secondary binding ligand, such as a second antibody and / or a biotin / avidin ligand binding arrangement, as is known in the art.
[0121] As noted above, a protein detection molecule (i.e., a binding ligand, such as an antibody or antibody fragment) can be linked to a detectable marker, whereby this marker would simply be detected, thus allowing the quantity of primary immune complexes in composition to be determined and / or quantified. Alternatively, the first antibody that binds to the primary immune complexes can be detected by means of a second binding ligand that has binding affinity to the antibody. In these cases, the second binding ligand may be linked to a detectable marker. The second binding ligand is often an antibody, which may thus be called a “secondary” antibody. The primary immune complexes are brought into contact with the secondary binding ligand or labeled antibody, under effective conditions and for a period of time sufficient to allow the formation of secondary immune complexes.The secondary immune complexes are then typically washed away to remove any antibodies. Petition 870260081961, dated 08 / 13 / 2026, pp. 197 / 305 42 / 69 or non-specifically bound labeled secondary ligands, and the remaining marker in the secondary immune complexes is then detected.
[0122] Other methods include the detection of primary immune complexes by a two-step approach. A second binding ligand, such as an antibody, which has binding affinity for the first binding ligand is used to form secondary immune complexes, as described above. After washing, the secondary immune complexes are brought into contact with a third binding ligand or antibody that has binding affinity for the second antibody, again under conditions and for a period of time sufficient to allow the formation of immune complexes (tertiary immune complexes). The third ligand or antibody can be linked to a detectable marker, allowing the detection of the tertiary immune complexes formed. This system can provide signal amplification, if desired.
[0123] As detailed above, immunoassays are linkage assays. Certain immunoassays are the various types of enzyme-linked immunosorbent assays (ELISAs) and / or radioimmunoassays (RIAs) known in the art. Immunohistochemical detection using tissue sections is also useful. It will be readily understood that detection is not limited to such techniques, and / or Western blot, spot blot, FACS and / or similar analyses may also be used.
[0124] In an exemplary ELISA, antibodies are immobilized on a selected surface exhibiting protein affinity, such as a well in a microtiter plate. Then, a test composition suspected of containing AP protein, such as a clinical sample (e.g., a biological sample obtained from the individual), is added to the wells. After ligation and / or washing to remove non-specifically bound immune complexes, the antibody-bound antigen can be detected. Detection is usually achieved by the addition of another (secondary) antibody that is bound to a detectable marker. This type of ELISA is a simple sandwich ELISA. Petition 870260081961, dated 08 / 13 / 2026, pp. 198 / 305 43 / 69 detection can also be achieved by adding a second antibody, followed by the addition of a third antibody having binding affinity for the second antibody, the third antibody being bound to a detectable marker.
[0125] In another exemplary ELISA, samples suspected of containing the antigen are immobilized on the well surface and / or then contacted with binding agents. After ligation and / or washing to remove non-specifically bound immune complexes, the bound anti-binding agents are detected. When the initial binding agents are bound to a detectable marker, the immune complexes can be detected directly. Again, the immune complexes can be detected using a second antibody that has binding affinity for the first binding agents, the second antibody being bound to a detectable marker.
[0126] Another ELISA, in which antigens are immobilized, involves the use of antibodies for detection. In this ELISA, antibodies labeled against an antigen are added to the wells, allowed to bind, and / or detected by means of their label. The amount of an antigen in an unknown sample is then determined by mixing the sample with the antibodies labeled against the antigen during incubation with coated wells. The presence of antigen in the sample acts to reduce the amount of antibody against the antigen available for binding to the well and thus reduces the final signal. This is also appropriate for the detection of antibodies against an antigen in an unknown sample, where unlabeled antibodies bind to antigen-coated wells and also reduce the amount of antigen available to bind the labeled antibodies.
[0127] Regardless of the format used, ELISAs have certain characteristics in common, such as coating, incubation and binding, washing to remove bound species not bound. Petition 870260081961, dated 08 / 13 / 2026, pp. 199 / 305 44 / 69 specifically and detection and / or quantification of linked immune complexes.
[0128] In ELISAs, it is probably more usual to use a secondary or tertiary detection medium rather than a direct procedure. Thus, after binding a protein or antibody to the well, coating with a non-reactive material to reduce the background and washing to remove unbound material, the immobilization surface is placed in contact with the biological sample to be tested under conditions effective to allow the formation of an immune complex (antigen / antibody). Detection of the immune complex then uses a labeled secondary binding ligand or antibody and a secondary binding ligand or antibody, in conjunction with a labeled tertiary antibody or a third binding ligand, and so on.
[0129] “Under conditions to permit the formation of an immune complex (antigen / antibody)” means conditions that allow or facilitate binding. Such conditions may include sample dilution, such as AP protein, tau oligomers, etc., and / or antibody composition with solutions such as BSA, bovine gamma globulin (BGG), or phosphate-buffered saline (PBS) / Tween. These added agents also tend to help reduce nonspecific antecedents.
[0130] “Suitable” conditions also mean that incubation is at a temperature or for a period of time sufficient to allow binding. Non-limiting exemplary incubation steps are typically around 1 to 2 to 4 hours, preferably at temperatures in the order of 25°C to 27°C, or may be overnight at around 4°C or more.
[0131] After all incubation steps in an ELISA, the contacted surface is washed to remove uncomplexed material. An example of a washing procedure includes washing with a solution such as PBS / Tween, or borate buffer. After the Petition 870260081961, dated 08 / 13 / 2026, pages 200 / 305 45 / 69 formation of specific immune complexes between the test sample and the originally bound material, and subsequent washing, minimal quantities of immune complexes can be determined.
[0132] To provide a means of detection, the second or third antibody may have an associated label to provide detection. This may be an enzyme that will generate color development upon incubation with an appropriate chromogenic substrate. Thus, for example, the first and second immune complexes may be contacted or incubated with a conjugated antibody of restlessness, glucose oxidase, alkaline phosphatase, or hydrogen peroxidase for a period of time and under conditions that favor the development of additional immune complex formation (e.g., incubation for 2 hours at room temperature in a solution containing PBS such as PBS-Tween).
[0133] After incubation with the labeled antibody, and after washing to remove unbound material, the amount of marker is quantified, for example, by incubation with a chromogenic substrate such as urea, or bromocresol purple, or 2,2'-azino-di-(3-ethylbenzothiazoline-6-sulfonic acid (ABTS)), or H2O2, in the case of peroxidase as an enzymatic marker. Quantification is then obtained by measuring the degree of color generated, for example, using a visible spectrum spectrophotometer.
[0134] As used herein, the singular forms a, eeo include the plural referents, unless the context clearly indicates otherwise. Therefore, for example, reference to “a nucleic acid” includes a plurality of such nucleic acids, reference to “a vector” includes a plurality of such vectors, and reference to “a virus” or “particle” includes a plurality of such viruses / particles.
[0135] As used herein, all numeric values or numeric ranges include whole numbers within such ranges and fractions of the values or whole numbers within ranges, unless the context clearly indicates otherwise. Therefore, for example, reference to Petition 870260081961, dated 08 / 13 / 2026, pp. 201 / 305 46 / 69 80% or more identity, includes 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, etc., as well as 81.1%, 81.2%, 81.3%, 81.4%, 81.5%, etc., 82.1%, 82.2%, 82.3%, 82.4%, 82.5%, etc., and so on.
[0136] A reference to an integer with more (greater) or less than includes any number greater or less than the reference number, respectively. Therefore, for example, a reference to less than 100 includes 99, 98, 97, etc. up to the number one (1); and less than 10 includes 9, 8, 7, etc. up to the number one (1).
[0137] As used in this request, all numerical values or ranges include fractions of the values and integers within such ranges and fractions of the integers within such ranges, unless the context clearly indicates otherwise. Therefore, to illustrate, a reference to a numerical range, such as 1-10, includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, as well as 1.1, 1.2, 1.3, 1.4, 1.5, etc., and so forth. The reference to a range of 1-50 therefore includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc., up to and including 50, as well as 1,1, 1,2, 1,3, 1,4, 1,5, etc., 2,1, 2,2, 2,3, 2,4, 2,5, etc., and so on.
[0138] The reference to a series of ranges includes ranges that combine the limit values of different ranges within the series. Therefore, to illustrate the reference to a series of ranges, for example, from 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-75, 75-100, 100-150, 150-200, 200-250, 250-300, 300-400, 400-500, 500-750, 750-1000, 1000-1500, 1500-2000, 2,000-2,500, 2,500-3,000, 3,000-3,500, 3,500-4,000, 4,000-4,500, 4,500-5,000, 5,500-6,000, 6,000-7,000, 7,000-8,000 or 8,000-9,000, includes intervals of 1050, 50-100, 100-1,000, 1,000-3,000, 2,000-4,000, etc.
[0139] The invention is generally disclosed herein using affirmative language to describe the numerous embodiments and aspects. The invention also specifically includes embodiments in which the particular subject matter is excluded, wholly or partially, such as substances or materials, Petition 870260081961, dated 08 / 13 / 2026, pp. 202 / 305 47 / 69 steps of the method and conditions, protocols or procedures. For example, in certain embodiments or aspects of the invention, materials and / or steps of the method are excluded. Therefore, although the invention is generally not expressed here in terms of what the invention does not include, aspects that are not expressly excluded in the invention are nevertheless disclosed here.
[0140] A number of embodiments of the invention have been described. However, a person skilled in the art, without departing from the spirit and scope of the invention, may make various alterations and modifications to the invention to adapt it to various uses and conditions. Consequently, the following examples are intended to illustrate, but not limit, the scope of the claimed invention. EXAMPLES Example 1 below is described in WO 2015 / 077473: Changes in the progression of amyloid deposition.
[0141] This Example studied changes in the progression of amyloid deposition in app / ps mice after overexpression of different ApoE isoforms via intraventricular injection of an adeno-associated virus serotype 4 (AAV4).
[0142] The ApoE epsilon 4 allele (ApoE ε4) is the primary genetic risk factor for Alzheimer's disease (AD), while inheritance of the rare ApoE epsilon 2 allele (ApoE ε2) reduces this risk by about half. However, despite the discovery of these strong genetic clues nearly 17 years ago, the mechanisms by which ApoE confers risk remain uncertain.
[0143] In order to decipher how the different ApoE isoforms (ApoE 2, 3 and 4) influence the formation and stability of fibrillar amyloid plaques, AAV4 vectors encoding each ApoE isoform were injected into the ventricle of 7-month-old APP / PS mice. Using in vivo multiphoton imaging, amyloid deposit populations were tracked at baseline and after exposure to ApoE over time. Petition 870260081961, dated 08 / 13 / 2026, pp. 203 / 305 48 / 69 over a two-month interval, thus allowing a dynamic view of amyloidosis progression in a live animal.
[0144] The kinetics of amyloid plaque deposition were observed to vary according to each isoform, such that mice injected with ApoE ε4 had a 38% increase in senile plaques while mice treated with ApoE ε2 showed a 15% decrease in the number of amyloid deposits compared to ApoE ε3 after 2 months. Post-mortem analysis confirmed these results and revealed the presence of human ApoE proteins decorating plaques in the cortex, reflecting a large diffusion of the protein throughout the parenchyma and its focal accumulation where Aβ peptides are deposited. Importantly, this increased ApoE ε4 protein content was also associated with more severe synaptic loss around the amyloid deposits.
[0145] Overall, the present data demonstrated that the overproduction of different ApoE isoforms was able to influence disease progression and may modulate the extent of synapse loss, one of the parameters that best correlates with cognitive impairment in patients with a. Intraventricular injection of AAV4-ApoE led to stable expression of huApoE and sustained detection of recombinant human ApoE protein (huApoE) in the brain.
[0146] In summary, GFP and huApoE were immunodetected in APP / PS mice injected with AAV4 vectors. The GFP signal can be seen throughout the ventricular area (upper panel) and in the cells lining the ventricle, as well as in human APOE.
[0147] To evaluate the current approach, AAV4-Venus (control), -ApoE2, -ApoE3, and -ApoE4 were injected into the ventricle of wild-type mice. Two months after injection, human ApoE proteins could be detected in the cortical parenchyma surrounding the Petition 870260081961, dated 08 / 13 / 2026, pages 204 / 305 49 / 69 amyloid deposits (note the 3H1 antibody; only non-specific antecedents were observed in mice injected with AAV4-GFP). Thus, a significant level of human ApoE was detected by ELISA in the brain, and immunohistological staining for Venus and ApoE confirmed the expression of the different transgenes by the cells lining the ventricle.
[0148] qRT-PCR experiments were performed to assess transgene mRNA levels. A standard curve was used to determine huApoE mRNA concentrations according to endogenous GAPDH levels. Samples from mice that were exposed for 2 or 5 months were included. An ELISA assay designed to specifically detect human APOE was performed on brain homogenates (Figure 1A, as shown in WO 2015 / 077473). Low levels of recombinant proteins could be detected in mice injected with AAV4-APOE compared to animals treated with AAV4-GFP, quantified by human APOE-specific ELISA (Figure 1B as shown in WO 2015 / 077473) and confirmed by Western blot. Overexpression of each APOE isoform differentially affects the progression of amyloidosis.
[0149] Two-photon imaging was used in vivo to track amyloid deposition over time in a live animal. Briefly, APP / PS mice (7 months old) were stereotaxically injected with AAV4 vectors encoding ApoE2, ApoE3, ApoE4, and Venus. After 1 week, a cranial window was implanted, and amyloid deposits were visualized over time after craniotomy. After 2 months, the animals were sacrificed, and post-mortem analyses were performed.
[0150] Two-photon images were prepared from APP / PS mice injected with AAV4-ApoE2, AAV4-ApoE3, or AAV4-ApoE4. Amyloid plaques could be detected after intraperitoneal injection of Methoxy-XO4 (5 mg / kg), and Texas Red dextran (70,000 Da molecular weight; 12.5 mg / ml in sterile PBS) was injected into a lateral vein of the Petition 870260081961, dated 08 / 13 / 2026, pages 205 / 305 50 / 69 tail to provide a fluorescent angiogram. Images were taken one week (= T0), one month, and two months after injection. The same fields were captured over time to track lesion progression. Few amyloid deposits appeared, while a few could not be detected during a two-month period.
[0151] A comprehensive analysis of in vivo images shows that the number of amyloid deposits increases significantly more rapidly in APP / PS mice injected with ApoE4 compared to animals treated with AAV4-ApoE3 and AAV4-Venus. In contrast, a small but significant decrease in plaque density is measured when AAV4-ApoE2 is used (Figure 2, as shown in document WO 2015 / 077473). A trend towards larger plaques is observed in APP / PS mice injected with AAV4-ApoE4 (p <0.06), but overall the plaque size remains constant. The summarized in vivo imaging data show that the overexpression of each APOE isoform differentially affects the progression of amyloid deposition in vivo. Injection of AAV4-ApoE2 leads to a slight decrease in amyloid density over time, while injection of AAV4-ApoE4 worsens amyloidosis. The size of amyloid plaques varies according to each ApoE isoform.
[0152] In vivo two-photon imaging allowed the monitoring of changes in the size of each amyloid deposit over a period of 2 months. The size of the plaques can remain stable, increase, or decrease over time. The distributions of size ratios between T1 / TO and T2 / T1 show that there is a shift towards larger amyloid plaques in mice injected with an AAV4-ApoE4 compared to the other groups (Figure 3, as shown in document WO 2015 / 077473). Post-mortem assessment of amyloid burden confirms the effects of ApoE2 and ApoE4 on amyloid deposition. Petition 870260081961, dated 08 / 13 / 2026, pages 206 / 305 51 / 69
[0153] Two months after AAV4 injection, post-mortem stereological evaluation revealed that animals injected with AAV4-ApoE4 had a higher density of amyloid plaques in the cortex, while no difference could be detected between the other groups (Figure 4A as shown in WO 2015 / 077473). This increased number of amyloid deposits was observed when the plaques were labeled with ThioS or Bam10. However, no change in the ratio between Bam10 and ThioS was detected. Five months after injection, the effects of each ApoE isoform were more pronounced compared to two months later (Figure 4B, as shown in WO 2015 / 077473). A significant increase in deposit density was observed when mice were injected with AAV4-ApoE4, while an inverse effect was detected with ApoE2. Again, no change in the ratio between Bam10 and ThioS was detected. Each form of ApoE differentially affects synaptic density around amyloid deposits.
[0154] Computed tomography was used to accurately determine the density of pre- and post-synaptic elements around amyloid deposits. This novel imaging method offers capabilities for high-resolution imaging of tissue molecular architecture. Computed tomography is based on ultra-thin sectioning of the specimen (70nm), immunostaining, and 3D reconstruction. Representative images of matrix tomography samples for amyloid plaque and the post-synaptic marker PSD95. Computed tomography images show that a decrease in the number of the post-synaptic marker PSD95 is observed around amyloid deposits, but this effect is abolished away from the plaques. Quantification of pre-(synapsin-1) and post-sympathetic markers in the vicinity or distant from plaques was determined in each group of mice injected with an AAV4 (Figure 5A-D as shown in WO 2015 / 077473). Extensive quantification of pre- and post-synaptic elements Petition 870260081961, dated 08 / 13 / 2026, pages 207 / 305 52 / 69 confirmed that a decreased density of synapsin 1 and PSD95 was associated with amyloid plaques, this effect being dramatically amplified when ApoE4 was overexpressed in the brains of APP / PS1 mice (Figure 5C, Figure 5D as shown in document WO 2015 / 077473). ApoE4 overexpression is associated with increased spine loss compared to other groups in the vicinity of amyloid deposits. Conversely, puncta synapsin density is higher in ApoE2-treated animals around plaques. Conclusion
[0155] Intraventricular injections of AAV virus serotype 4 led to sustained and chronic overproduction of soluble recombinant proteins throughout the brain parenchyma. Overexpression of ApoE2, ApoE3, and ApoE4 differentially affected the course of pathology in APP / PS mice, such that amyloid burden progression was significantly increased when ApoE4 was injected compared to ApoE3. On the other hand, ApoE2 was associated with protective effects, and few amyloid deposits were undetectable two months after injection. Post-mortem immunohistological analysis confirmed the adverse effect of ApoE4. Sustained overproduction of ApoE4 exacerbated the synapse loss observed around amyloid deposits compared to ApoE3, while ApoE2 had a moderate effect. This study demonstrated a direct connection between ApoE isoforms, amyloidosis progression, and synapse loss in vivo. Example 2 below is described in document WO 2015 / 077473 and shows a successful treatment of CNS disorders through the administration of CSF: Treatment of CNS disorders through cerebrospinal fluid (CSF) in large mammals.
[0156] In order to achieve gene therapy for brain disorders, such as Alzheimer's disease, it was necessary to determine whether long-term steady-state levels of enzymes Petition 870260081961, dated 08 / 13 / 2026, pp. 208 / 305 53 / 69 therapeutics could be achieved in a mammal. It was discovered that ependymal cells (cells located in the ventricles of the brain) can be transduced and secrete an enzyme directed to the cerebrospinal fluid (CSF). It was determined that adeno-associated virus (AAV4) can transduce the ependyma in a mouse model with high efficiency. (Davidson et al, PNAS, 28: 3428-3432, 2000). In mice, there was a normalization of stored substrate levels in the brain after treatment with AAV4.
[0157] It was investigated whether global delivery of a vector could be effectively achieved in order to reach stable enzyme levels in the CSF. First, a vector needed to be found to transduce ependymal cells (cells lining the ventricles) in the brains of larger mammals. Studies were conducted in a canine model of LINCL and a non-human primate model of LINCL. LINCL dogs are normal at birth but develop neurological signs around 7 months, testable cognitive deficits at ~5-6 months, seizures at 10-11 months, and progressive visual loss.
[0158] An adeno-associated virus (AAV) was selected as the vector because of its small size (20 nm), most of its genetic material can be removed (stripped) so that there are no viral genes, and so that it is replication incompetent. It was previously tested whether adeno-associated virus type 4 (AAV4) vectors could mediate overall functional and pathological improvements in a murine model of mucopolysaccharidosis type VII (MPS VII) caused by beta-glucuronidase deficiency (Liu et al., J. Neuroscience, 25(41):9321-9327, 2005). Recombinant AAV4 vectors encoding beta-glucuronidase were injected unilaterally into the lateral ventricle of MPS VII mice with established disease. The transduced ependyma expressed high levels of recombinant enzyme, with the secreted enzyme penetrating cerebral and cerebellar structures as well as the brainstem. Immunohistochemical studies Petition 870260081961, dated 08 / 13 / 2026, pages 209 / 305 Studies 54 / 69 revealed a close association between the recombinant enzyme and the cerebral microvasculature, indicating that beta-glucuronidase reached the cerebral parenchyma through the perivascular spaces lining the blood vessels. Aversive associative learning was tested by context-based fear conditioning. Compared to age-matched heterozygous controls, affected mice exhibited impaired conditioned fear response and context discrimination. This behavioral deficit was reversed 6 weeks after gene transfer in MPS VII mice treated with AAV4 beta-glucuronidase. The data show that ependymal cells may serve as a source of enzymatic secretion in the cerebral parenchyma and CSF.
[0159] Surprisingly, however, when these studies were extended to large mammals (i.e., dogs and non-human primates), the AAV4 vectors were not effective in targeting the ependyma in these animals. Instead, an AAV2 vector needed to be used. Briefly, rAAV2 was generated encoding TPP1 (AAV2-CLN2) and injected intraventricularly to transduce the ependyma (Liu et al., J. Neuroscience, 25 (41): 9321-9327, 2005). TPP1 is the LINCL-deficient enzyme. The data indicated that ependymal transduction in the NHP brain resulted in a significant increase of the enzyme in the CSF. The results indicated elevated levels of TPP1 activity in several brain regions, where the vertical axis shows % control of the activity (Figure 7, as shown in WO 2015 / 077473).
[0160] In the first dog that was treated, vector delivery was suboptimal, but still exhibited CLN2 activity in the brain. Subsequent dogs underwent ICV delivery with stereotaxy. The cognitive abilities of the treated dogs were found to have improved significantly compared to an untreated dog, as measured by T-maze performance (Figure 8 as shown in WO 2015 / 077473). Furthermore, the effects of ICV delivery of AAV2-CLN2 on Petition 870260081961, dated 08 / 13 / 2026, pages 210 / 305 55 / 69 LINCL dog model were very pronounced. In the untreated animal (- / -), large ventricles are present, while the brains of the untreated control and treated animals did not exhibit ventricles. After delivery of AAV.TPP1 to the ventricles of LINCL dogs, detectable enzymatic activity was observed in several brain regions, including the cerebellum and upper spinal cord. In two additional live affected dogs, cerebral atrophy was significantly attenuated, longevity increased, and cognitive function was improved. Finally, in the NHP, we show that this method can achieve TPP1 activity levels 2-5 times higher than the wild type.
[0161] Several AAV vectors were generated and tested to determine the ideal ITR and capsid combination. Five different combinations were produced, as it was determined that the AAV2 ITR was most effective: AAV2 / 1 (i.e., AAV2 ITR and AAV1 capsid), AAV2 / 2, AAV2 / 4, AAV2 / 5, and AAV2 / 8. AAV2 / 2 was found to work much better in large mammals (dogs and NHP), followed by AAV2 / 8, AAV2 / 5, AAV2 / 1, and AAV2 / 4. This was quite surprising because the order of effectiveness of the viral vectors is the opposite of what was observed in mice.
[0162] Thus, the present work showed that ventricular lining cells can be a source of recombinant enzyme in the CSF for distribution throughout the brain, and that AAV2 / 2 is an effective vehicle for delivering therapeutic agents, such as the gene encoding CLN2 (TPP1) in dogs and non-human primates. Example 3 below is described in WO 2015 / 077473 and shows the effect of different ApoE isoforms administered via an AAV vector in the CNS: Human APOE isoforms delivered via gene transfer differentially modulate Alzheimer's disease, amyloid deposition, clearance, and neurotoxicity.
[0163] Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder and has become a major Petition 870260081961, dated 08 / 13 / 2026, pp. 211 / 305 56 / 69 public health problem. Among the susceptibility genes associated with the late-onset sporadic form of AD, the apolipoprotein E ε4 allele (APOE - gene; ApoE - protein) is by far the most significant genetic risk factor. The presence of one copy of APOE ε4 substantially increases the risk of developing the disease by a factor of 3 compared to the more common APOE ε3 allele, while two copies lead to a 12-fold increase. Interestingly, APOE ε2 has the opposite impact and is a protective factor, such that inheritance of this specific allele decreases the age-adjusted risk of AD by about half compared to APOE3 / 3. The average age of onset of dementia also corresponds to these risk profiles, with APOE4 / 4 carriers having onset in the mid-60s and APOE2 / 3 carriers in the early 90s, a shift of almost 3 decades, while APOE3 / 3 individuals have an age of onset in the middle - in the mid-1970s.
[0164] The mechanism by which ApoE affects AD is controversial. The accumulation of Aβ-containing senile plaques in the hippocampus and cortex of patients is believed to play a central role in AD, because all known genes responsible for the rare autosomal dominant forms of the disease participate in the production of Aβ peptides. Interestingly, the APOE genotype has been shown to strongly affect the extent of amyloid deposition in AD patients, as well as the amount of neurotoxic soluble oligomeric Aβ detected in autopsy samples. ApoE isoforms have been suggested to differentially influence cerebrovascular integrity and affect the efflux of Aβ peptides across the blood-brain barrier, thus modulating the accumulation of amyloid aggregates around blood vessels (cerebral amyloid angiopathy or CAA). Furthermore, ApoE has also been directly implicated in neurodegeneration and neuronal plasticity.The effects of ApoE2 have been relatively understudied in these contexts.
[0165] Genetically modified animals expressing Petition 870260081961, dated 08 / 13 / 2026, pages 212 / 305 57 / 69 Human APOE2, -E3, and -E4 have a similar amyloid load ranking order as humans, consistent with the hypothesis that different ApoE isoforms impact plaque initiation and / or growth. However, further studies are needed to dissect the mechanisms of ApoE-mediated effects on existing amyloid deposits and neurodegeneration. To overcome this knowledge gap, we used a gene transfer approach in which adeno-associated virus vectors expressing the various APOE alleles (or GFP control) are injected into the lateral ventricle to primarily transduce the ependyma, which then acts as a biological factory to deliver ApoE into the cerebrospinal fluid and interstitial fluid.Next, we used intravital multiphoton microscopy to track the effects of various ApoE isoforms on plaque formation, growth, and, in the case of ApoE2, dissolution, as well as in vivo microdialysis approaches to monitor ApoE and Aβ biochemical variables in ISF and matrix tomography to assess changes in Aβ-associated neurotoxicity.
[0166] ApoE isoforms influence the levels of soluble oligomeric Aβ in the ISF, the rate of fibrillation and Aβ deposition, the stability of amyloid deposits once formed, their clearance, and the extent of peri-plaque neurotoxic effects. In fact, mice treated with ApoE4 exhibit an increased amount of soluble A13, a higher density of fibrillar plaques, an exacerbation of synaptic element loss, and an increased number of neuritic dystrophies around each deposit, while a relative protective effect was observed with ApoE2. These data support the hypothesis that APOE alleles mediate their effect on AD primarily through Aβ, and highlight ApoE as a therapeutic target. RESULTS Intraventricular injection of AAV4-APOE leads to stable expression of APOE and sustained production of human ApoE in Petition 870260081961, dated 08 / 13 / 2026, pp. 213 / 305 58 / 69 brain
[0167] Apolipoprotein E is a naturally secreted protein, produced primarily by astrocytes and microglial cells, and can diffuse throughout the brain parenchyma. We exploited this property by injecting an AAV serotype 4 encoding for GFP (control) or each APOE allele into the cerebral lateral ventricles of 7-month-old APP / PS1 mice. Considering the large brain areas affected by the characteristic lesions of AD, this strategy offers a significant advantage compared to multiple intraparenchymal injections.
[0168] Two months after injection, transduced cells were detected in the choroid plexus and ependymis lining the ventricle, thus confirming the functionality of the AAV4 vectors. Using species-specific antibodies, both human and murine ApoE proteins were also detected by ELISA (Figs. 9A, 9B, and 15A as shown in WO 2015 / 077473) and Western Blot. The concentration of human apolipoprotein E was observed to reach 20 mg / mg of total protein (Fig. 9A, as shown in WO 2015 / 077473), representing approximately 10% of endogenous murine apoE (Fig. 9B as shown in WO 2015 / 077473). The presence of this modest additional amount of human ApoE did not detectably alter endogenous murine apoE protein levels (Fig. 15A as shown in document WO 2015 / 077473). A small but statistically significant decrease was observed between 2 and 5 months after AAV4 injection (Fig. 15B as shown in document WO 2015 / 077473).However, human protein levels remained detectable compared to the control group, suggesting that AAV4-mediated transduction provided a platform for sustained production of the recombinant protein secreted throughout the parenchyma. In fact, human ApoE proteins can be detected around amyloid deposits of APP / PS1 mice throughout the cortical mantle, where endogenous marine apoE protein is known to accumulate. Petition 870260081961, dated 08 / 13 / 2026, pages 214 / 305 59 / 69
[0169] Next, we assessed the presence of human ApoE in interstitial fluid (ISF), an extracellular compartment that also contains highly biologically active Aβ-soluble species. Because of the relatively small amount of ApoE detected throughout the brain lysate, we injected multiple apoE KO mice with each AAV4-APOE vector and screened for the presence of the human protein using highly sensitive, but non-species-specific, antibodies. Using a microdialysis technique, we confirmed the presence of ApoE in the ISF of animals injected with apoE KO.
[0170] Overall, these data confirm that a single intracerebroventricular injection of AAV4 was sufficient to lead to sustained production of a protein of interest throughout the brain parenchyma and within the ISF, and that the ependymal / choroid plexus can be used as a “biological pump” to deliver potentially therapeutic proteins to the brain. Infusion of ApoE isoforms differentially affects amyloid peptides and plaque deposition.
[0171] APP / PS1 mice were transduced with vectors expressing GFP or the various ApoE isoforms for 5 months before euthanasia. An analysis of amyloid plaque burden revealed that, after 5 months, a significant increase in amyloid deposit density was observed in the cortex of animals injected with AAV4-APOE4 compared to those expressing APOE2. Plaque density in mice treated with AAV4-GFP and AAV4-APOE3 were not different from each other at an intermediate level (Fig. 16A as shown in document WO 2015 / 077473).
[0172] The concentrations of Aβ40 and Aβ42 peptides measured from formic acid extracts mimicked the changes observed in amyloid plaque content, such that an increased concentration of amyloid peptides was found in mice. Petition 870260081961, dated 08 / 13 / 2026, pages 215 / 305 60 / 69 expressing the APOE4 allele (Fig. 16B as shown in WO 2015 / 077473), and an opposite effect was detected with APOE2 after 5 months. The content of Aβ40 and Aβ42 peptides in the soluble fraction in TBS was similarly affected by the injection of each AAV-APOE (Fig. 16C as shown in WO 2015 / 077473). Furthermore, the ratio between aggregated and soluble A13 peptides remained unchanged by ApoE exposure, thus suggesting that the overexpression of each distinct isoform of human ApoE concomitantly modulates both fibrillar and soluble amyloid species.
[0173] Overexpression of each ApoE isoform for only 2 months leads to smaller effects than those observed in the 5-month study. However, a significant increase in amyloid plaque density within the cortical area of mice injected with AAV4APOE4 was observed compared to the other experimental groups (Fig. 16A, as shown in document WO 2015 / 077473). This paralleled the amount of AP contained in the formic acid fraction (Fig. 16C as shown in document WO 2015 / 077473), demonstrating a predominant effect of this specific variant. TBS-soluble Αβ 40 / 42 species showed only a tendency to be smaller or larger when AAV4-APOE2 or AAV4APOE4, respectively, were expressed for 2 months (data not shown).
[0174] To determine whether the presence of human ApoE isoforms may reflect an early change in the degree of Aβ fibrillation, we also measured the relationship between robust immunostaining for AP using Bam10 (which labels all amyloid deposits) and Thio-S (which only stains dense core) 2 months post-injection. No change was detected between the 3 isoforms, suggesting that there was no differential effect on the distribution of dense and diffuse amyloid deposit populations between the experimental groups at this time point (Fig. 16B as shown in WO 2015 / 077473). These data indicate that longer exposure to ApoE variants has stronger effects on amyloid deposition. Petition 870260081961, dated 08 / 13 / 2026, pages 216 / 305 61 / 69 amyloid than the shorter exposure.
[0175] It has been suggested that ApoE plays a role in the transport of Aβ across the blood-brain barrier. To test whether exposure to ApoE isoforms can modulate the efflux of AP peptides across the blood-brain barrier, the concentration of Aβ 40 in the plasma of each injected animal was measured. It was observed that the plasma content of human Aβ in both AAV4-APOE3 and AAV4-APOE4 mice injected intracerebroventricularly was lower compared to AAV4-APOE2 and AAV4GFP (Fig. 10D as shown in document WO 2015 / 077473). This suggests that the E3 and E4 variants help retain AP in the central nervous system compartment, consistent with the relative increase in AP concentrations in the brain parenchyma observed and with previous data suggesting an increased half-life of AP due to ApoE.
[0176] APOE4 carriers are more susceptible to neurovascular dysfunction, and blood-brain barrier degradation has recently been shown to be favored in APOE4 transgenic mice, even in the absence of amyloid deposition. In order to assess whether an intraventricular injection of an AAV4-APOE in APP / PS could compromise BBB integrity, post-mortem staining with Prussian blue was performed. Despite the presence of a few sparsely scattered hemosiderin-positive focal areas throughout the brain in all groups, no obvious differences were observed between any of the experimental animal groups. Expression of ApoE isoforms modulates the kinetics of amyloidosis progression.
[0177] ApoE4 was associated with an increased density of amyloid deposits, while the opposite effect was observed with ApoE2 after 5 months. This may reflect changes in amyloid deposition rates, clearance, or both. To assess how ApoE variants affect the dynamic progression of amyloidosis, we used imaging of Petition 870260081961, dated 08 / 13 / 2026, pages 217 / 305 62 / 69 two-photons in vivo and we followed the kinetics of amyloid plaque formation and clearance. Mice received an intraventricular injection with an AAV4 vector at 7 months of age, and a cranial window was implanted one week after the injection to perform the first imaging session (TO). After 1 (T1) and 2 months (T2), amyloid deposits were visualized in the same fields of view. Mice were sacrificed for post-mortem analysis after the second imaging session.
[0178] The vast majority of amyloid deposits remained stable, although occasional new plaques could be detected in the small visualization volume over the two-month period. Furthermore, on rare occasions, a methoxy-positive plaque that was photographed at the beginning of the experiment could not be detected after one or two months, suggesting that some plaques might be removed. Over time, we observed an overall increase in the volumetric density of amyloid deposits, with the density at T2 averaging 23% higher than at T1. The rate of amyloid progression was faster in APP / PS1 mice treated with ApoE4, while animals exposed to ApoE2 showed a significant reduction in amyloid deposit density compared to GFP (0.66), ApoE3 (0.67), and ApoE4 (0.74) after 2 months (Figs. 11A, 11B as shown in document WO 2015 / 077473).It is important to highlight that the ApoE2 alterations reflect a decrease relative to baseline, directly demonstrating, for the first time, the active, non-immune-mediated release of plaques. In contrast to data obtained from APOE transgenic animals, these results demonstrate that inducing a modest increase in the amount of ApoE can affect the ongoing amyloidogenic process even after amyloid deposition has begun.
[0179] Next, we assessed the growth of a single amyloid plaque by measuring the ratio of the cross-sectional area of individual deposits between T1 / TO and T2 / T1. Differences were detected. Petition 870260081961, dated 08 / 13 / 2026, pages 218 / 305 63 / 69 between the groups at T1 (T1 / T0 ratio), but not at T2 (T2 / T1 ratio, Fig. 12 as shown in document WO 2015 / 077473), suggesting that the presence of human ApoE variants primarily affects plaque growth during the first month after exposure, but this parameter does not differ thereafter. In particular, the size of amyloid deposits increased significantly more in mice treated with ApoE4 compared to ApoE2 and ApoE3, suggesting that not only the number of plaques but also their size were exacerbated by this allele. ApoE4, therefore, affects both the seeding of AP peptides and the size of pre-existing plaques. Synaptic density around amyloid deposits is exacerbated by ApoE3 and ApoE4 isoforms compared to ApoE2.
[0180] Synapse loss is a parameter that correlates best with cognitive impairment. We recently showed that the presence of ApoE4 is associated with higher levels of synaptic oligomeric Αβ in the brains of patients with human Alzheimer's disease and leads to a significant decrease in synapse density around amyloid plaques compared with ApoE3 (RM Koffie et al., Effects of apolipoprotein E4 in Alzheimer's disease are mediated by synaptotoxic oligomeric beta-amyloid. Brain 135, 2155 (Jul, 2012); T. Hashimoto et al., Apolipoprotein E, especially Apolipoprotein E4, increases beta-amyloid peptide oligomerization. J Neurosci 32, 15181 (Oct 24, 2012)). Furthermore, recent in vitro evidence has demonstrated that ApoE4 failed to protect against Aβ-induced synapse loss (M. Buttini et al.Modulation of Alzheimer's-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on the isoform, aging, and overexpression of beta-amyloid peptides, but not on plaque formation. J Neurosci 22, 10539 (December 15, 2002); A. Sen, DL Alkon, Nelson TJ, Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased protein expression. Petition 870260081961, dated 08 / 13 / 2026, pp. 219 / 305 64 / 69 kinase C epsilon. J Biol Chem 287, 15947 (May 4, 2012)). Therefore, it was hypothesized that a continuous and diffuse distribution of each ApoE isoform may not only differentially affect the kinetics of Aβ deposition and clearance in the brains of APP / PS mice, but also the integrity of synapses surrounding amyloid deposits.
[0181] The densities of pre- and post-synaptic elements (respectively, synapsin-1 and PSD95) were determined using array tomography, a high-resolution technique based on immunofluorescence staining of ultrathin tissue sections (KD Micheva, SJ Smith, Array tomography: a novel tool for imaging the molecular architecture and ultrastructure of neural circuits. Neuron 55, 25 (July 5, 2007); RM Koffie et al., Oligomeric amyloid beta associates with post-synaptic densities and correlates with excitatory loss of synapses near senile plaques. Proc Natl Acad Sci USA, 106, 4012 (March 10, 2009)). Since oligomeric amyloid species were found to be highly concentrated in the vicinity of amyloid deposits, synapsin-1 and PSD95 puncta were quantified either far from (> 50μm) or close to (<50μm) the plaques using previously established protocols (RM Koffie et al.Oligomeric beta-amyloid is associated with postsynaptic densities and correlates with the loss of excitatory synapses in senile plaques. Proc Nall Acad Sci USA 106, 4012 (March 10, 2009). We observed that the loss of presynaptic elements near plaques was exacerbated when APOE3 or APOE4 was expressed, which was not the case after injection of AAV4-APOE2 or AAV4-GFP (Fig. 13A as shown in document WO 2015 / 077473). In contrast, the density of postsynaptic lacrimal puncta remained unchanged between GFP, ApoE2, and ApoE3 injected into mice, while animals treated with ApoE4 showed a significant loss of PSD95 around amyloid deposits, thus reinforcing the deleterious effect of ApoE4 on the neurotoxic effects of Aβ (Fig 13C, as shown in document WO 2015 / 077473). When the density of synaptic elements... Petition 870260081961, dated 08 / 13 / 2026, pages 220 / 305 65 / 69 was evaluated in areas located far from amyloid deposits (> 50μm), no difference could be detected between the groups, suggesting that there is no effect of human ApoE variants per se on synaptic density, but an important effect of ApoE isoforms on Aβ-induced neurotoxicity. The relative synaptic loss observed with ApoE3 and ApoE4 is therefore directly related to the presence of Aβ peptides around each plaque (at a distance <50 μm from its edge).
[0182] As an additional neuropathological parameter, we also evaluated the number of neuritic dystrophies associated with amyloid deposits in APP / PS1 mice injected with AAV4. In addition to a decrease in column density around them, senile plaques also cause a more general neuropil alteration with an increase in neurite curvature and the appearance of swollen dystrophies. These pathological changes are likely attributable to soluble oligomeric Aβ species that are enriched in a region within 50μm of the plaque surface. ApoE4 overexpression was observed exacerbating the formation of SMI312-positive neuritic dystrophies associated with amyloid deposits compared to GFP, ApoE2, and ApoE3 (Fig. 13C as shown in document WO 2015 / 077473). This result confirms the observation that the ApoE4 isoform has the strongest effect and not only modulates plaque formation but also affects amyloid-associated neurotoxicity. Human ApoE proteins modify the oligomeric amount of ApoE contained in the interstitial fluid of another rat model of...
[0183] Next, we addressed the question of whether the presence of different ApoE isoforms in the ISF can alter the amount of soluble amyloid species in the same extracellular compartment. We chose to inject another model of apoE, Tg2576 mice, in order to validate our previous findings in a different transgenic mouse line. Tg2576 mice overexpress the mutated form of APP. Petition 870260081961, dated 08 / 13 / 2026, pages 221 / 305 66 / 69 mice containing the Swedish mutation exhibit a much milder phenotype than APP / PS1 mice at a given age. We injected cohorts of animals aged 16–18 months, so amyloid deposits were already present at the time of AAV4-APOE transduction. Three months after gene transfer, a microdialysis probe was inserted into the hippocampus and samples were collected to characterize the initial changes associated with each APOE variant within the ISF.
[0184] We observed that the concentration of oligomeric Aβ species measured using the specific 82E1 / 82E1 ELISA assay was significantly higher (by 42 ± 7%) after injection of AAV4-APOE4 compared with AAV4-APOE2 (Fig. 14, as shown in WO 2015 / 077473), suggesting that the presence of ApoE may modulate the nature of amyloid aggregates in this extracellular compartment. Furthermore, when total Aβ40 and Aβ42 were evaluated in the ISF, the same trends were observed, but did not reach significance (Fig. 17A, as shown in WO 2015 / 077473), suggesting that the presence of different ApoE isoforms in the ISF influences the amyloid peptide aggregation state somewhat more than the total amount.
[0185] As expected, postmortem biochemical analyses of Tg2576 brains from mice exposed to various ApoE isoforms showed that the concentration of Aβ42 in the formic acid fraction was significantly increased in ApoE4-treated animals (Fig 17B. As shown in document WO 2015 / 077473), confirming in a second transgenic model our observations in APP / PS1 mice.
[0186] Taken together, these biochemical measures suggest that ApoE expression in Tg2576 mice induces similar changes in amyloid biology as observed in APP / PS1 mice. Importantly, an early change is observed in the oAβ content within the ISF, where these neurotoxic species can interact directly with synaptic terminals. Petition 870260081961, dated 08 / 13 / 2026, pages 222 / 305 67 / 69 Example 4 Conclusions from Examples 1-3
[0187] Previous studies in Examples 1-3 described in WO 2015 / 077473 show the efficacy of treating an AAV vector with a transgene encoding a protective ApoE isoform when administered into the CNS of an animal model of Alzheimer's disease. The previous studies therefore support the proposition that a protective ApoE isoform delivered to the CNS via an AAV vector is a treatment for Alzheimer's disease. Example 5: Exemplary Tests for ApoE Detection APOE ELISA
[0188] Specific ELISA assays were used to detect human and endogenous murine APOE proteins. Briefly, ELISA plates were coated overnight with goat anti-APOE antibody (to detect murine APOE) or 1.5 µg / mL WUE4 antibody (to detect human APOE) and blocked with 1% skim milk diluted in PBS for 1.5 h at 37°C. Recombinant human apoE proteins were used as standards (for the human-specific assay, Biovision) or mouse brain extract internal standards (for the murine-specific assay) and samples were diluted in ELISA buffer (0.5% BSA and 0.025% Tween-20 in PBS) and incubated overnight. After washing, specific detection antibodies for humans (Millipor goat antibody; 1:10000) or mice (Abcam ab20874; 1:2000) were used, respectively, followed by 1.5 h of incubation with an appropriate HRP-conjugated secondary antibody.Signal development was performed using TMB substrate before stopping the solution with H3PO4. Colorimetric results were measured at 450nm. Quantification of Aβ
[0189] The concentrations of Αβ40 and Αβ42 were determined by sandwich ELISA BNT-77 / BA-27 (for Αβ40) and BNT-77 / BC-05 (for Αβ42) (Wako), according to the manufacturer's instructions. Αβ oligomers were quantified using the 82E1 / 82E1 sandwich ELISA. Petition 870260081961, dated 08 / 13 / 2026, pages 223 / 305 68 / 69 (ImmunoBiological Laboratories), in which the same N-terminal antibodies (residues 1-16) were used for capture and detection (W. Xia et al., A specific enzyme immunoassay to measure beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer's disease. Arch Neurol 66, 190 (Feb, 2009)). Example 6 Examples of AAV capsid sequences VP1 Capsid AAV-LK03 (SEQ ID NO:1): MAADGYLPDWLEDNLSEGIREWWALQPGAPKPKANQQHQDNARGLVLPGYKYLGPGNGLD KGEPVNAADAAAALEXDKAYDQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQ AKKRLLEPLGLVEAKTAPGKKRPVDQSPQEPDSSSGVGKSGKQPARKRLNFGQTGDSE SVPDPQPLGEPPAAPTSLGSNTMASGGGAPMADNNEGADGVGNSSGNWHCDSQWLGDRVI TTSTRTWALPTYNNLYKQISSQSGASNDNHYFGYSTPWGYFDFNRFHCHFSPRDWQRLI NNNWGFRPKKLSFKLFNIQVKEVTQNDGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQG CLPPFPADVFMVPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYTFEDVPF HSSYAHSQSLDRLMNPLIDQYLYYLNRTQGTTSGTTNQSRLLFSQAGPQSMSLQARNWLP GPCYRQRLSKTANDNNNSNFTAAWTAANKHLNKHLNGSHGVHFKH LIFGKEGTTASNAELDNMITDEEEIRTTNPVATEQYGTWANNLQSSNTAPTTRTTVNDQG ALPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQIMIKNTPVPANPPT TFSPAKFASFITQYSTGQVVEIEWELQKENSKRTVNKWNVVNDSVNDSVNDQG YSEPRPIGTRYLTRPL Amino acid sequence of AAV VP1 capsid 4-1 (SEQ ID NO: 2): MAADGYLPDWLEDNLSEGIREWWDLKPGAPPKPKANQQKQDNGRGLVLPGYKYLGPFNGLD KGEPVNAADAAALEHDKAYDQQLQAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQ 121 AKKRVLEPLGLVESPVKTAPGKKRPVEPSPQRSPDSSTGIGKKGQQPAKRLNFGQTGDS 181 ESVPDPQPIGEPPAAPSGVGPNTMAAGGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRV 241 ITTSTRTWALPTYNNLYLYQQISNGTSGGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQ 301 RLINNNWGFRPKRLNFKLFNIQVKEVTQNEGTKTIANNLTSTIQVFTDSEYQLPYVLGSA 361 HQGCLPPFPADVFMIPQYGYLTLNNGSQAV GRSSFYCLEYFPSQMLRTGNNFEFSYNFED 421 VPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQSTGGTAGTQQLLFSQAGPNNMSAQAKNW 481 LPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMATHKDDEFFFFS 541 GVLMFGKQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVVADNLQQQNAAPIVGAVNS 601 QGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADP 661 PTTFNQKLASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYKSTNVDFAVNTE 721 GTYSEPRPIGTRYLTRNL Petition 870260081961, of 13 / 08 / 2026, p. 224 / 305 69 / 69 Amino acid sequence of AAV VP2 capsid 4-1 (SEQ ID NO: 3): TAPGKKRPVEPSPQRSPDSSTGIGKKGQQPAKKRLNFGQTGDSESVPDPQPIGEPPAAPSGVGPNT MAAGGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNLYKQISNGTS GGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNEG TKTIANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCL EYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQSTGGTAGTQQLLF SQAGPNNMSAQAKNWLPGPCYRQQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMAT HKDDEERFFPSSGVLMFGKQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVVADNLQQQNAAP IVGAVNSQGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPP TTFNQAKLASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPI GTRYLTRNL Amino acid sequence of AAV VP3 capsid 4-1 (SEQ ID NO: 4): MAAGGGAPMADNNEGADGVGSSSGNWHCDSTWLGDRVITTSTRTWALPTYNNLYKQISNGTS GGSTNDNTYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTQNEG TKTIANNLTSTIQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCL EYFPSQMLRTGNNFEFSYNFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTQSTGGTAGTQQLLF SQAGPNNMSAQAKNWLPGPCYRQRVSTTLSQNNNSNFAWTGATKYHLNGRDSLVNPGVAMAT HKDDEERFFPSSGVLMFGKQGAGKDNVDYSSVMLTSEEEIKTTNPVATEQYGVADNLQQQNAAP IVGAVNSQGALPGMVWQNRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGLKHPPPQILIKNTPVPADPP TTFNQKLASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSTNVDFAVNTEGTYSEPRPI GTRYLTRNL Petition 870260081961, of 13 / 08 / 2026, p. 225 / 305
Claims
1 / 2 CLAIMS 1. Use of a composition comprising a recombinant adeno-associated virus particle (rAAV) comprising an AAV capsid protein and a vector, characterized in that it is used in the manufacture of a medicament that assists in the treatment of Alzheimer's disease in a mammal that has an ApoE ε4 allele, said vector comprising a nucleic acid encoding a protective isoform of ApoE inserted between a pair of terminal inverted repeats of AAV, wherein said nucleic acid is operatively linked to a specific liver promoter, and said vector infects liver cells and is expressed in liver cells so that the protective isoform of ApoE is secreted into the mammalian circulation, such that the protective isoform of ApoE is delivered to the mammalian central nervous system, wherein the protective isoform of ApoE is human ApoE ε2.
2. Use, according to claim 1, characterized by the circulation levels of ApoE4 being reduced relative to the total circulation of ApoE levels.
3. Use, according to claim 1 or 2, characterized in that the nucleic acid encoding the protective isoform of ApoE has reduced cytosine-guanine dinucleotide (CpG) compared to a non-reduced CpG nucleic acid encoding the ApoE isoform.
4. Use, according to any one of claims 1 to 3, characterized in that the vector further comprises one or more introns, an expression control element, a polynucleotide padding sequence and / or a poly A signal or a combination thereof.
5. Use, according to any one of claims 1 to 4, characterized in that the pair of ITRs is derived from or comprises a sequence of any one of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, LK01, LK02, LK03, AAV 4-1, ITRs AAV-2i8, or a mixture thereof. Petition 870260112066, dated 10 / 30 / 2026, p. 7 / 13 2 / 2 6. Use, according to any one of claims 1 to 5, characterized in that the AAV capsid protein is derived from or comprises a sequence of any one of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, LK01, LK02, LK03, AAV 4-1, ITRs AAV-2i8, or a mixture thereof.
7. Use, according to any one of claims 1 to 6, characterized in that empty AAV capsids are rAAV particles that are formulated with an amount less than or equal to rAAV vector particles; or with an excess of 1.0 to 100 times empty AAV capsids relative to rAAV particles. Petition 870260112066, dated 10 / 30 / 2026, p. 8 / 13
